var title_f11_39_11888="Seldinger cricothyrotomy step 3";
var content_f11_39_11888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seldinger cricothyrotomy technique: Step 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thread the guidewire through the catheter into the trachea. Remove the catheter, sliding it over the guidewire.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11888=[""].join("\n");
var outline_f11_39_11888=null;
var title_f11_39_11889="EUS mucinous cystic neopl";
var content_f11_39_11889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    EUS of pancreatic mucinous cystic neoplasm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Corresponding endoscopic ultrasound image of the 3 cm mucinous cystic neoplasm depicted in Picture 3.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11889=[""].join("\n");
var outline_f11_39_11889=null;
var title_f11_39_11890="Undecylenic acid and derivatives: Pediatric drug information";
var content_f11_39_11890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Undecylenic acid and derivatives: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12146?source=see_link\">",
"    see \"Undecylenic acid and derivatives: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/30/30179?source=see_link\">",
"    see \"Undecylenic acid and derivatives: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fungi-Nail&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12146?source=see_link\">",
"      see \"Undecylenic acid and derivatives: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical: Apply as needed twice daily for 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fungi-Nail&reg;: Undecylenic acid 25% (29.57 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Clean and dry the affected area before topical application; if the solution is sprayed or applied onto the affected area, allow area to air dry; ointment or cream should be applied at night, the powder may be applied during the day or used alone when a drying effect is needed",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of athlete's foot (tinea pedis), ringworm (except nails and scalp), prickly heat, jock itch (tinea cruris), diaper rash, and other minor skin irritations due to superficial dermatophytes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to undecylenic acid and derivatives or any component; fungal infections of the scalp or nails",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not apply to blistered, raw, or oozing areas of skin or over deep wounds or puncture wounds",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resolution of skin infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Undecylenic acid is a fatty acid with fungistatic activity that retards proliferation of the fungus by altering the conditions of growth; zinc undecylenate provides an astringent action that aids in the reduction of inflammation and irritation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Improvement in erythema and pruritus may be seen within 1 week after initiation of therapy",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/30/30179?source=see_link\">",
"      see \"Undecylenic acid and derivatives: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with the eye; do not inhale the powder",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12870 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11890=[""].join("\n");
var outline_f11_39_11890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050673\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050669\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235826\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050676\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050675\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050679\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050668\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300194\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223585\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050672\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050667\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050678\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050671\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12146?source=related_link\">",
"      Undecylenic acid and derivatives: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/30/30179?source=related_link\">",
"      Undecylenic acid and derivatives: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_39_11891="Hybridization silence";
var content_f11_39_11891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hybridization silence of Faecalibacterium prausnitzii",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hybridization silence of Faecalibacterium prausnitzii in a patient with idiopathic diarrhea (orange fluorescence, x200). Bacteria are suppressed at the center of stool whereas their concentration and fluorescence at the surface are well preserved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11891=[""].join("\n");
var outline_f11_39_11891=null;
var title_f11_39_11892="Diphenoxylate and atropine: Patient drug information";
var content_f11_39_11892=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diphenoxylate and atropine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/56/9094?source=see_link\">",
"     see \"Diphenoxylate and atropine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37397?source=see_link\">",
"     see \"Diphenoxylate and atropine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lomotil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lomotil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Diphenoxylate is used to treat loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691226",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Atropine stops abuse of this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a child younger than 2 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701962",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diphenoxylate, atropine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Loose stools caused by infection, liver disease, or yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to take this drug as you have been told by your doctor. Do not use more than you were told to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696206",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use the dropper that comes with this drug to measure the drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12387 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11892=[""].join("\n");
var outline_f11_39_11892=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161161\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161162\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014326\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014325\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014330\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014331\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014333\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014328\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014329\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014334\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014335\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/56/9094?source=related_link\">",
"      Diphenoxylate and atropine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37397?source=related_link\">",
"      Diphenoxylate and atropine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_39_11893="Insertion of contraceptive diaphragm";
var content_f11_39_11893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F85545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F85545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Insertion of contraceptive diaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 686px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A, B, C show insertion of a diaphragm. D shows removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11893=[""].join("\n");
var outline_f11_39_11893=null;
var title_f11_39_11894="Lenalidomide: Patient drug information";
var content_f11_39_11894=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lenalidomide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     see \"Lenalidomide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2407571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Revlimid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6027963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Revlimid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects. Women must use 2 helpful kinds of birth control during care. A man must use a latex condom even if he has had a vasectomy. A written explanation of the risks must be presented, read, and signed by the patient before getting this drug. If a patient is younger than 18 years of age, this written warning must be signed by a parent or legal guardian.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700477",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe blood cell count problems may happen. Report any fever, sore throat, mouth sores, infections, easy bruising, or purple \"splotches\" on your skin to your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause blood clots in your veins or lungs. Call your doctor right away if you have any chest pain, shortness of breath, or pain or swelling of the legs or arms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lenalidomide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701068",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of childbearing age, but are not using 2 kinds of birth control or if you are planning to get pregnant during your care or within 4 weeks after care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a blood clotting problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a lactose-free diet, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697770",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust before care begins, during care, and for 4 weeks after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 1 month after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man, do not donate sperm while using this drug and for 1 month after stopping.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other kinds of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, pregnancy tests will be given before starting this drug, while you are on this drug, and for 4 weeks after you have stopped this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2821639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been less than 12 hours since a normal dose, take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696587",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been 12 hours or more since the missed dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11554 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11894=[""].join("\n");
var outline_f11_39_11894=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2407571\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027963\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020081\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020083\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020082\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020087\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020088\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020090\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020085\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020086\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020091\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020092\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=related_link\">",
"      Lenalidomide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_39_11895="Preparation of blood components";
var content_f11_39_11895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preparation of blood components",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/39/11895/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11895/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/39/11895/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11895/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/39/11895/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11895/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/39/11895/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood",
"    <strong>",
"     components",
"    </strong>",
"    are those products derived from whole blood (or platelet-rich plasma) collected from normal donors by phlebotomy (or hemapheresis) using the technique of differential centrifugation. These products are prepared in blood centers or hospital laboratories, and should be distinguished from plasma",
"    <strong>",
"     derivatives",
"    </strong>",
"    , which are fractionated from large volumes (thousands of liters) of plasma in large, industrial manufacturing sites.",
"   </p>",
"   <p>",
"    This topic review will discuss the preparation of blood components. Use of these blood components is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link\">",
"     \"Clinical use of plasma components\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The manufacture of plasma derivatives and their general use is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of whole blood (ie, plasma, cryoprecipitate, red cells, lymphocytes, granulocytes, platelets) have different requirements for optimum storage and preservation of function. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelets left in units of red cells at refrigerator temperatures clump and interact with red cells and plasma proteins, and rapidly lose hemostatic effectiveness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      are removed by filtration during transfusion.",
"     </li>",
"     <li>",
"      Coagulation factors, especially factors V and VIII, are somewhat labile even at 4&ordm;C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, to get the maximum benefit from a unit of donated whole blood, plasma, red cells, and platelets must be separated from each other and stored at different temperatures and under different conditions (",
"    <a class=\"graphic graphic_table graphicRef57166 \" href=\"UTD.htm?16/31/16891\">",
"     table 1",
"    </a>",
"    ). As a result, red cells can be stored for up to 42 days at refrigerator temperatures, plasma or cryoprecipitate can be stored frozen for one year, and platelets remain viable and active for up to five days when stored at room temperature.",
"   </p>",
"   <p>",
"    Good manufacturing practices, with which manufacturers of blood components must comply, involve careful monitoring of these conditions and strict adherence to specified quality control measures. The Food and Drug Administration regulates all blood collection and component and derivative production as a pharmaceutical manufacturing process, including the registration, evaluation, and acceptance of blood donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Blood donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;From a regulatory and a quality point of view, proper manufacture of blood components begins with the careful recruitment and selection of safe donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At present, approximately 98 percent of allogeneic blood collected comes from volunteer donors. Another 2 percent comes from autologous donors (ie, those donating their own blood prior to a scheduled surgical procedure). Most institutions restrict the use of autologously donated blood only to the person donating the blood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"       \"Preoperative autologous blood donation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A small amount of blood comes from patients with disorders that require periodic phlebotomy, such as hereditary hemochromatosis. Such patients, if otherwise qualified, may donate more frequently than routine donors, who are only eligible to donate blood eight weeks following a prior donation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link&amp;anchor=H6#H6\">",
"       \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Use of blood withdrawn for therapeutic purposes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 0.4 percent of blood comes from directed donors, ie, donors who are asked to donate for a specific recipient. Since there is frequently a subtle level of coercion involved in such donations, many experts do not feel such blood is as safe as that from the truly voluntary donor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11061?source=see_link\">",
"       \"Directed (designated) blood donation programs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Plasma fractionation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of plasma collected for further manufacture (fractionation) in the United States comes from donors who are paid a nominal fee. Most such commercial plasma collection operations are highly regulated and carefully monitored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BLOOD COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the donation site, whole blood is collected from an antecubital vein, after the site of puncture has been cleansed and sanitized with iodine-alcohol or chlorhexidine-based solutions. A clean, uncomplicated venipuncture is required for good flow so as to avoid platelet clumping and fibrin formation.",
"   </p>",
"   <p>",
"    The whole blood is collected into a plastic bag containing an anticoagulant-preservative solution and should be gently and regularly mixed with that solution as the bag fills. In the United States, 500 mL is collected by most blood centers. Some volume adjustments can be made for autologous collections in which the donor weighs less than the FDA required 50 kg.",
"   </p>",
"   <p>",
"    Blood can be collected into a single, double, triple, or quadruple blood pack so that the components can be prepared by differential centrifugation within an integrated, sterilized system. For some pediatric uses, multiple smaller volume packs are integrally attached, primarily for use in newborns.",
"   </p>",
"   <p>",
"    Thus, a single whole blood donation can provide one unit each of red cells, platelets, cryoprecipitate, and frozen cryoprecipitate-poor plasma for transfusion or for further manufacture into plasma derivatives. Most blood is collected into double (red cells plus plasma) or triple (red cells, platelets, plasma) bags. Whole blood is almost never used unmodified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of red blood cells for transfusion\", section on 'Storage bags'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTICOAGULANT/PRESERVATIVE SOLUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of preservative and anticoagulant solutions are available, all based on the use of sodium citrate as an anticoagulant. Until the 1980s, the anticoagulant and preservatives were in a single solution, such as ACD (acid-citrate-dextrose) or CPD (citrate-phosphate- dextrose). Most of the whole blood collected now in the United States is anticoagulated in the initial collection bag and then modified.",
"   </p>",
"   <p>",
"    As soon as possible, but within 72 hours of donation, the red cells are spun down and an integrally attached solution of saline, glucose, adenine, and sometimes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    is added to the red cells. This additive solution results in better viability and biochemical function of the red cells than is achieved with storage in an anticoagulant solution alone. The presence of adenine in the preservative solution better preserves ATP levels (but does not do as well for 2,3-DPG), providing for less red cell membrane breakdown and longer red cell survival.",
"   </p>",
"   <p>",
"    Additive solutions currently in use allow for storage of red cells for up to 42 days at 1 to 6&ordm;C. Newer additive solutions are under investigation but, short of cryopreservation, which allows storage of red cells for up to 10 years, red cells still have a limited storage time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of red blood cells for transfusion\", section on 'Frozen deglycerolized red cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The platelets, if to be transfused, must be removed and processed within eight hours of collection. If plasma is frozen within eight hours, the transfusable product is labeled fresh frozen plasma (FFP). If the plasma is removed and frozen within 24 hours, it is labeled frozen plasma (FP-24). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link\">",
"     \"Clinical use of plasma components\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otherwise, the plasma is removed within the 72-hour time limit and sent for fractionation into gamma globulin and albumin. Plasma used for the fractionation of coagulation factors must be of the same quality as the \"fresh frozen\" plasma for transfusion, or at least separated within 24 hours after collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BLOOD COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major blood components are red cell and platelet concentrates, fresh frozen plasma, and cryoprecipitate (",
"    <a class=\"graphic graphic_table graphicRef53854 \" href=\"UTD.htm?41/3/42043\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Red cell concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell concentrates are largely used for the treatment of blood loss or anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many blood centers, up to 100 percent of red cells are subjected to filtration to reduce leukocytes prior to storage, such that, nationwide, approximately 75 percent of red cells are leukoreduced prior to transfusion. These leukocyte-reduced (LR) red cells are used to mitigate febrile nonhemolytic transfusion reactions, HLA sensitization and platelet immune refractoriness, cytomegalovirus transmission, and other unwanted results of transfusing unnecessary leukocytes and cytokines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Platelet concentrates",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Single donor apheresis platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of convenience, more efficient means for performing bacterial testing, in-process reduction of contaminating leukocytes, the possibility for HLA matching, and the reduced risk of infectious disease transmission per transfusion episode due to exposure to a single rather than multiple donors, most platelet transfusions in the United States are obtained from platelets collected from single donors during a plateletpheresis collection.",
"   </p>",
"   <p>",
"    Such preparations, previously called \"single donor\" platelets, contain a minimum of 3 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets in a volume of about 300 mL. Thus, a plateletpheresis or single donor platelet product is equivalent to four to six whole blood-derived concentrates from whole blood donations.",
"   </p>",
"   <p>",
"    In one systematic review, it was concluded that there were an insufficient number of trials to determine the relative clinical benefits (ie, efficacy and safety) of apheresis platelet concentrates versus whole blood-derived platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Platelets derived from whole blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of platelet transfusion doses are provided by platelet concentrates prepared from individual whole blood units within eight hours of collection. In much of the rest of the world, platelet concentrates are prepared by a buffy coat method within a 24-hour time frame. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558382031#H558382031\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Platelet collection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These whole blood-derived platelet concentrates are administered in groups of four to eight, sometimes being pooled into a single pack prior to transfusion. These pools or packs can also be leukocyte-reduced using filters designed specifically for platelets. Indications for using LR platelets are basically the same as those for LR red cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558382031#H558382031\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Platelet collection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After separation of the red cells from the platelet-rich plasma at a relatively slow centrifugal speed in a preparatory centrifuge at room temperature, the red cells are refrigerated and processed as above. The platelets are then concentrated from the platelet-rich plasma using a faster or \"harder\" spin, separated into a third, attached integral pack from the blood collection set, suspended in a volume of about 50 mL of plasma, and stored on gently rotating trays at 22&ordm;C for up to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/4\">",
"     4",
"    </a>",
"    ]. In some countries, a platelet additive solution has been used in place of plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/5\">",
"     5",
"    </a>",
"    ]. In Canada and Europe an alternative manufacturing process (the buffy coat method) is used.",
"   </p>",
"   <p>",
"    The required testing of the donor sample effectively removes at least one day, and sometimes more, of shelf life. The container for the platelets is of slightly different composition that allows for freer exchange of respiratory gases (oxygen, carbon dioxide) between the outside air and the plasma-suspended platelets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each random platelet concentrate from one unit of blood should contain 5.5 x 10",
"    <sup>",
"     10",
"    </sup>",
"    platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/6\">",
"     6",
"    </a>",
"    ], and have a pH greater than 6.2 at the end of the storage period. Currently, most platelet concentrates contain about 7 x 10",
"    <sup>",
"     10",
"    </sup>",
"    platelets in a volume of about 50 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Leukocyte-reduced platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet concentrates, like red cells, contain contaminating leukocytes that may cause adverse reactions in some recipients and may elaborate inflammatory cytokines during storage. As a result, the use of LR platelet transfusions that are filtered prior to storage has become important to prevent platelet refractoriness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H20#H20\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Prevention of alloimmunization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemapheresis equipment, used to collect single donor platelets for transfusion has been engineered to reduce leukocyte contamination significantly during or just after the plateletpheresis procedure. This obviates a separate filtration step, using a sterile connecting device, and the process has been incorporated into many of the hemapheresis machines currently on the market. Hemapheresis equipment is increasingly being used for some red cell and plasma collections, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bacterial contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Storage of platelets in such a rich medium (plasma) and at room temperature poses risks of bacterial growth if there has been an unrecognized bacteremia in the donor or contamination of the unit by skin flora. Contamination is only occasionally visible to eye inspection (eg, via discoloration of the product or evidence for coagulation). Apheresis and prepooled and stored platelets are tested for bacterial contamination by automated culture techniques. Such testing reduces the risk of bacterial contamination by approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link&amp;anchor=H1969743#H1969743\">",
"     \"Transfusion transmitted bacterial infection\", section on 'Detection of contamination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pathogen reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of a photochemical treatment, using a psoralen compound (amotosalen) and exposure to long wavelength ultraviolet light, to inactivate viruses, bacteria, protozoa, and leukocytes for use in the transfusion of platelets and plasma has been actively under investigation since the early 2000s. This pathogen inactivated platelet product has been approved for use in several European countries and tens of thousands of these pathogen inactivated platelet units have been transfused without any documented adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/10,13-18\">",
"     10,13-18",
"    </a>",
"    ]. However, a meta-analysis of five randomized controlled trials (four using the amotosalen treated product and one using a riboflavin treated product) has concluded that use of such products has been associated with reduced post-transfusion corrected count increments as well as an increase in clinically significant, but not life-threatening, bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelets treated with a different inactivation method (Mirasol technology utilizing riboflavin and ultraviolet light) have also begun to be used in a few European countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fresh frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fresh frozen plasma (FFP) and FP-24 refer to plasma that is separated and frozen at -18 C&ordm; within eight hours or 24 hours, respectively, of collection of whole blood and can then be stored for one year.",
"   </p>",
"   <p>",
"    FFP and FP-24 contain all the requisite plasma coagulation factors in amounts only slightly reduced (such as factor VIII) from that of fresh plasma. However, none of them is in concentrated form, and FFP should not be used as a source of specific clotting factors that can be obtained in safer and purer form [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrinogen is best given, if needed, as cryoprecipitate or, when available, as a concentrate. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cryoprecipitate'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H12#H12\">",
"       \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Fibrinogen concentrate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Specific concentrates of factor VIII, factor IX and von Willebrand factor are available as plasma derivatives. Some concentrates (eg, factor XI, factor XIII) are available in Europe and other countries, but have not yet been approved for use in the United States. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H11#H11\">",
"       \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Coagulation factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Documented deficiencies of factors V, VII, XI and XIII can be treated with FFP or FP-24 if necessary, although concentrates of factors XI and XIII are available in some countries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H10#H10\">",
"       \"Rare (recessively inherited) coagulation disorders\", section on 'Fresh frozen plasma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thawed plasma, which is FFP or FP-24 thawed and then stored at 1 to 6&ordm; C for up to five days is used routinely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical use of plasma components\", section on 'Thawed plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cryoprecipitate",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a unit of FFP is allowed to thaw for 24 hours at 4&ordm;C, a milky flocculum consisting of several cold insoluble globulins can be separated from the liquid plasma. These cryoprecipitable proteins include fibrinogen (factor I), antihemophilic factor (factor VIII), fibrin stabilizing factor (factor XIII) and von Willebrand factor (vWF), including the larger von Willebrand factor multimers thought to be important in the pathogenesis of thrombotic thrombocytopenic purpura (TTP).",
"   </p>",
"   <p>",
"    This cryoprecipitate, in a volume of 10 to 15 mL, is then refrozen at -18&ordm;C for use up to one year. The residual cryoprecipitate-poor plasma can be frozen for transfusion (previously used for the treatment of TTP during plasma exchange therapy) or sent for further manufacture into albumin and gamma globulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Cryoprecipitate-poor plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryoprecipitate, first developed in 1965, became a mainstay of treatment and prevention of bleeding in patients with hemophilia and changed dramatically the ability of these patients to lead a more normal life. Its use in hemophilia A was almost entirely supplanted by factor VIII fractionated from large volumes of human plasma, a process which infected most users during the early years of the HIV epidemic. Currently, the use of recombinant-DNA manufactured factor VIII has supplanted this source of factor VIII. Fractionated and",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    treated and recombinant forms of factor IX are used for the treatment of hemophilia B. With current methods of viral inactivation, none of these plasma derivatives has been associated with the risk of transmitting hepatitis C, hepatitis B, or HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11895/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryoprecipitate is still useful for the replacement of fibrinogen and von Willebrand factor and the treatment of uremic bleeding in appropriate circumstances, and for the treatment and prevention of severe factor XIII deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link&amp;anchor=H13#H13\">",
"     \"Platelet dysfunction in uremia\", section on 'Cryoprecipitate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of von Willebrand disease\", section on 'Preparations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H26#H26\">",
"     \"Rare (recessively inherited) coagulation disorders\", section on 'Factor XIII deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma or blood components are biological products prepared by differential centrifugation of whole blood or plasma in a blood center or hospital laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Available preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood components commonly used in transfusion medicine include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frozen plasma (FFP or FP-24) (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Fresh frozen plasma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Red blood cell concentrates (packed RBCs) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Red cell concentrates'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Platelet concentrates (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Platelet concentrates'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cryoprecipitate (cryo) and Cryoprecipitate (cryo)-poor plasma (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Cryoprecipitate'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Granulocyte concentrates (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=see_link\">",
"       \"Granulocyte transfusions\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Usage guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Usage guidelines for the above-noted products are discussed separately, as follows (",
"    <a class=\"graphic graphic_table graphicRef53854 \" href=\"UTD.htm?41/3/42043\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frozen plasma &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Red blood cell concentrates &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"       \"Use of red blood cells for transfusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"       \"Indications for red cell transfusion in the adult\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"       \"Massive blood transfusion\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Platelet concentrates &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link\">",
"       \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link\">",
"       \"Refractoriness to platelet transfusion therapy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cryoprecipitate &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Granulocyte concentrates &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=see_link\">",
"       \"Granulocyte transfusions\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/1\">",
"      Westphal RG. Donors and the United States blood supply. Transfusion 1997; 37:237.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services. The 2007 National Blood Collection and Utilization Survey, Washington, DC. DHHS, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/3\">",
"      Heddle NM, Arnold DM, Boye D, et al. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/4\">",
"      Skripchenko A, Myrup A, Thompson-Montgomery D, et al. Periods without agitation diminish platelet mitochondrial function during storage. Transfusion 2010; 50:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/5\">",
"      Kerkhoffs JL, Eikenboom JC, Schipperus MS, et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108:3210.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Standards, American Association of Blood Banks. Standards for Blood Banks and Transfusion Services, 26th ed, American Association of Blood Banks, Bethesda 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/7\">",
"      Kruskall MS. The perils of platelet transfusions. N Engl J Med 1997; 337:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/8\">",
"      Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007; 47:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/9\">",
"      Su LL, Kamel H, Custer B, et al. Bacterial detection in apheresis platelets: blood systems experience with a two-bottle and one-bottle culture system. Transfusion 2008; 48:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/10\">",
"      Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008; 112:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/11\">",
"      Murphy WG, Foley M, Doherty C, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/12\">",
"      Benjamin RJ, Kline L, Dy BA, et al. Bacterial contamination of whole-blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion 2008; 48:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/13\">",
"      McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/14\">",
"      van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/15\">",
"      Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/16\">",
"      Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006; 46:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/17\">",
"      Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/18\">",
"      Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/19\">",
"      Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/20\">",
"      Yazer MH, Cortese-Hassett A, Triulzi DJ. Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C. Transfusion 2008; 48:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/21\">",
"      von Heymann C, Keller MK, Spies C, et al. Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days. Transfusion 2009; 49:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/22\">",
"      Scott E, Puca K, Heraly J, et al. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6&deg;C storage. Transfusion 2009; 49:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11895/abstract/23\">",
"      Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39:1160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7943 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11895=[""].join("\n");
var outline_f11_39_11895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Blood donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Plasma fractionation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BLOOD COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTICOAGULANT/PRESERVATIVE SOLUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BLOOD COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Red cell concentrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Platelet concentrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Single donor apheresis platelets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Platelets derived from whole blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Leukocyte-reduced platelets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bacterial contamination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pathogen reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fresh frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cryoprecipitate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Available preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Usage guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/31/16891\" title=\"table 1\">",
"      Storage of blood components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/3/42043\" title=\"table 2\">",
"      Blood replacement products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11061?source=related_link\">",
"      Directed (designated) blood donation programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=related_link\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_39_11896="Imipenem and cilastatin: Pediatric drug information";
var content_f11_39_11896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Imipenem and cilastatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/36/38472?source=see_link\">",
"    see \"Imipenem and cilastatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7652?source=see_link\">",
"    see \"Imipenem and cilastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Primaxin&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imipenem and Cilastatin for Injection;",
"     </li>",
"     <li>",
"      Primaxin&reg; I.V. Infusion;",
"     </li>",
"     <li>",
"      RAN&trade;-Imipenem-Cilastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Carbapenem",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage recommendations are based on",
"     <b>",
"      imipenem",
"     </b>",
"     component; not the preferred carbapenem for preterm infants due to cilastatin accumulation and possible seizures (Blumer, 1996; Freij, 1985;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012; Reed, 1990); not recommended for CNS infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General dosing, susceptible infection",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bodyweight &le;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA &le;7 days: 20 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA 8-28 days: 25 mg/kg/dose every 12 hours;",
"     <b>",
"      Note:",
"     </b>",
"     For ELBW neonates (bodyweight: &lt;1 kg) and PNA &le;14 days, may consider an extended dosing interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight &gt;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA &le;7 days:  25 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PNA 8-28 days: 25 mg/kg/dose every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/36/38472?source=see_link\">",
"      see \"Imipenem and cilastatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage recommendations are based on",
"     <b>",
"      imipenem",
"     </b>",
"     component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General  dosing, susceptible infection",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 1-3 months: 100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants &ge;3 months, Children, and Adolescents: 60-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Burkholderia pseudomallei",
"      </i>",
"      (melioidosis):",
"     </b>",
"     Infants, Children, and Adolescents: I.V.: Initial: 60-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours for at least 10 days; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"     ; continue parenteral therapy until clinical improvement, then switch to oral therapy if tolerated and/or appropriate (Currie, 2003; White, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Intra-abdominal infection, complicated:",
"     </b>",
"     Children and Adolescents: I.V.: 60-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum dose: 500 mg (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Peritonitis (CAPD)",
"     </b>",
"     (Warady, 2000): Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 200 mg per liter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pulmonary exacerbation, cystic fibrosis:",
"     </b>",
"     Infants, Children, and Adolescents: I.V.: 100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"     ; efficacy may be  limited due to rapid development of resistance (Doring, 2009; Zobell, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Weight &ge;70 kg: I.V.:  250-1000 mg every 6-8 hours; maximum: 4000 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     For adults weighing &lt;70 kg, refer to Dosing Adjustment in Renal Impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Mild infections:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Rarely a suitable option in mild infections; normally reserved for moderate-severe cases: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Fully susceptible organisms: 250 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderately susceptible organisms: 500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Moderate infections:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Fully susceptible organisms: 500 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderately susceptible organisms: 500 mg every 6 hours or 1000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Fully susceptible organisms: 500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderately susceptible organisms: 1000  mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maximum daily dose should not exceed 50 mg/kg or 4000 mg/day, whichever is lower",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      <i>",
"       Pseudomonas",
"      </i>",
"      infections:",
"     </b>",
"     I.V.: 500 mg every 6 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Higher doses may be required based on organism sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Urinary tract infection, uncomplicated:",
"     </b>",
"     I.V.: 250 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Urinary tract infection, complicated:",
"     </b>",
"     I.V.: 500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Infants, Children, and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Manufacturer&rsquo;s labeling: Patient weight &lt;30 kg and impaired renal function (not defined):  Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     The following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     GFR 30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 7-13 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 7.5-12.5 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 7.5-12.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Intermittent hemodialysis (IHD): 7.5-12.5 mg/kg/dose every 24 hours (administer after hemodialysis on dialysis days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Peritoneal dialysis (PD): 7.5-12.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Continuous renal replacement therapy (CRRT): 7-13 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Adults: Manufacturer&rsquo;s labeling: Reduce dose based on creatinine clearance and/or body weight:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Imipenem and Cilastatin Dosage in Renal Impairment",
"     </caption>",
"     <col align=\"left\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         Reduced I.V. Dosage Regimen Based on",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance (mL/minute/1.73 m",
"         <sup>",
"          2",
"         </sup>",
"         ) and/or Body Weight &lt;70 kg",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"left\">",
"       </th>",
"       <th align=\"center\" colspan=\"5\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Body Weight (kg)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"left\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          &ge;70",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          60",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          50",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          40",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          30",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 1000 mg/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 1500 mg/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 2000 mg/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 3000 mg/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Total daily dose for normal renal function: 4000 mg/day",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &ge;71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         41-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         750 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         21-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q8h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q6h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q8h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         6-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg q12h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;5 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     should not receive imipenem/cilastatin unless hemodialysis is instituted within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Patients weighing &lt;30 kg with impaired renal function should not receive imipenem/cilastatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Use the dosing recommendation for patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     6-20 mL/minute; administer dose after dialysis session and every 12 hours thereafter",
"     <b>",
"      or",
"     </b>",
"     250-500 mg every 12 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Peritoneal dialysis: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     6-20 mL/minute (Somani, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CVVH: Loading dose of 1000 mg followed by either 250 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CVVHD: Loading dose of 1000 mg followed by either 250 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CVVHDF: Loading dose of 1000 mg followed by either 250 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Data suggest that 500 mg every 8-12 hours may provide sufficient time above MIC to cover organisms with MIC values &le;2 mg/L; however, a higher dose of 500 mg every 6 hours is recommended for resistant organisms (particularly",
"     <i>",
"      Pseudomonas",
"     </i>",
"     spp) with MIC &ge;4 mg/L or deep-seated infections (Fish, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: Imipenem 250 mg and cilastatin 250 mg; imipenem 500 mg and cilastatin 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primaxin&reg; I.V.: Imipenem 250 mg and cilastatin 250 mg [contains sodium 18.8 mg (0.8 mEq)]; imipenem 500 mg and cilastatin 500 mg [contains sodium 37.5 mg (1.6 mEq)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer by I.V. intermittent infusion; final concentration should not exceed 5 mg/mL; in fluid-restricted patients, a final concentration of 7 mg/mL has been administered at some institutions (Taketomo, 2009); doses &le;500 mg may be infused over 15-30 minutes; doses &gt;500 mg should be infused over 40-60 minutes. If nausea and/or vomiting occur during administration, decrease the rate of I.V. infusion.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F182093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, mannitol 2.5%, mannitol 5%, mannitol 10%, NS, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, anidulafungin, aztreonam, caspofungin, cefepime, cisatracurium, diltiazem, docetaxel, famotidine, fludarabine, foscarnet, granisetron, insulin (regular), linezolid, melphalan, methotrexate, ondansetron, propofol, remifentanil, tacrolimus, teniposide, thiotepa, tigecycline, vasopressin, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amiodarone, amphotericin B cholesteryl sulfate complex, azithromycin, drotrecogin alfa, etoposide phosphate, fluconazole, gemcitabine, lorazepam, meperidine, midazolam, milrinone, sargramostim, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Filgrastim, gallium nitrate, idarubicin, telavancin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store intact vial of powder for injection below 25&deg;C (77&deg;F).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Per the manufacturer, solutions further diluted with D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS or NS are stable for 4 hours at room temperature and 24 hours under refrigeration; additional stability data suggests solutions further diluted with NS are stable for 11 hours at room temperature (25&deg;C) or 72 hours under refrigeration (4&deg;C) and when further diluted with D",
"     <sub>",
"      5",
"     </sub>",
"     W are stable for 36 hours under refrigeration (4&deg;C).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of documented multidrug-resistant gram-negative infection of the lower respiratory tract, urinary tract, intra-abdominal, gynecologic, bone and joint, septicemias, endocarditis, and skin and skin structure due to organisms proven or suspected to be susceptible to imipenem/cilastatin (FDA approved in all ages); treatment of multiple organism infection in which other agents have an insufficient spectrum of activity or are contraindicated due to toxic potential; therapeutic alternative for treatment of gram-negative sepsis in immunocompromised patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Imipenem may be confused with ertapenem, meropenem",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Primaxin&reg; may be confused with Premarin&reg;, Primacor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F182092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Oliguria/anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis/thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, abnormal urinalysis, acute renal failure, alkaline phosphatase increased, anaphylaxis, anemia, angioneurotic edema, asthenia, bilirubin increased, bone marrow depression, BUN/creatinine increased, candidiasis, confusion, cyanosis, dizziness, drug fever, dyspnea, encephalopathy, eosinophilia, erythema multiforme, fever, flushing, gastroenteritis, glossitis, hallucinations, hearing loss, hematocrit decreased, hemoglobin decreased, hemolytic anemia, hemorrhagic colitis, hepatitis (including fulminant onset), hepatic failure, hyperchloremia, hyperhidrosis, hyperkalemia, hypersensitivity, hyperventilation, hyponatremia, hypotension, jaundice, lactate dehydrogenase increased, leukocytosis, leukopenia, myoclonus, neutropenia (including agranulocytosis), palpitation, pancytopenia, paresthesia, pharyngeal pain, polyarthralgia, polyuria, positive Coombs' test, prothrombin time increased, pruritus vulvae, pseudomembranous colitis, psychic disturbances, rash, resistant",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     , somnolence, Stevens-Johnson syndrome, thoracic spine pain, thrombocythemia, thrombocytopenia, tinnitus, tongue papillar hypertrophy, toxic epidermal necrolysis, transaminases increased, tremor, urticaria, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to imipenem/cilastatin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with history of CNS disorders including seizures or who are predisposed and in patients with a history of hypersensitivity to penicillins, cephalosporins, or other beta-lactams; use with caution and adjust dose in patients with impaired renal function.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and occasionally fatal hypersensitivity reactions have been reported in patients receiving beta-lactam therapy; careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other beta-lactams before initiating imipenem. Pseudomembranous colitis has been reported in patients receiving imipenem; prolonged use may result in superinfection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Valproic acid (VPA) serum concentrations may be significantly decreased by concurrent carbapenem use leading to breakthrough seizures. VPA/divalproex sodium dosage adjustment may not adequately overcome this interaction; concurrent use with valproic acid/divalproex sodium is not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medications. Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. Seizures have been reported with imipenem therapy in children with meningitis; imipenem is not recommended in pediatric patients with CNS infections.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the neurotoxic effect of Imipenem. Imipenem may increase the serum concentration of CycloSPORINE (Systemic). Imipenem may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Carbapenems may decrease the serum concentration of Divalproex.  Management: Concurrent use of carbapenem antibiotics with divalproex is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Imipenem. May increase risk of seizures.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Imipenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Carbapenems may decrease the serum concentration of Valproic Acid.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events have not been observed in animal reproduction studies. Due to pregnancy induced physiologic changes, some pharmacokinetic parameters of imipenem/cilastatin may be altered. Pregnant women have a larger volume of distribution resulting in lower serum peak levels than for the same dose in nonpregnant women. Clearance is also increased.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, and hematologic function tests; bowel movement frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits cell wall synthesis by binding to all of the penicillin-binding proteins with greatest affinity for PBP 1 and PBP 2; cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the proximal renal tubules",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Rapidly and widely to most tissues and fluids including sputum, pleural fluid, peritoneal fluid, interstitial fluid, bile, aqueous humor, and bone; highest concentrations in pleural fluid, interstitial fluid, and peritoneal fluid; only low concentrations penetrate into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imipenem: 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cilastatin: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Imipenem is metabolized in the kidney by dehydropeptidase; cilastatin prevents imipenem metabolism by this enzyme; cilastatin is partially metabolized in the kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, both drugs: Prolonged with renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates (Freij, 1985):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Imipenem: 1.7-2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cilastatin: 3.9-6.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: Imipenem: 1.2 hours (Blumer, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, both drugs: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: When imipenem is given with cilastatin, urinary excretion of unchanged imipenem increases to 70%; 70% to 80% of a cilastatin dose is excreted unchanged in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content: 250 mg vial contains 0.8 mEq; 500 mg vial contains 1.6 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahonkhai VI, Cyhan GM, Wilson SE, et al, &ldquo;Imipenem-Cilastatin in Pediatric Patients: An Overview of Safety and Efficacy in Studies Conducted in the United States,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):740-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/2687787/pubmed\" id=\"2687787\" target=\"_blank\">",
"        2687787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, \"Pharmacokinetic Determinants of Carbapenem Therapy in Neonates and Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1996, 15(8):733-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/8858691/pubmed\" id=\"8858691\" target=\"_blank\">",
"        8858691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Currie BJ, \"Melioidosis: An Important Cause of Pneumonia in Residents of and Travellers Returned from Endemic Regions,\"",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2003, 22(3):542-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/14516149/pubmed\" id=\"14516149\" target=\"_blank\">",
"        14516149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      D&ouml;ring G, Conway SP, Heijerman HG, et al, \"Antibiotic Therapy Against",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      in Cystic Fibrosis: A European Consensus,\"",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2000, 16(4):749-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/11106223/pubmed\" id=\"11106223\" target=\"_blank\">",
"        11106223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fish DN, Teitelbaum I, and Abraham E, \"Pharmacokinetics and Pharmacodynamics of Imipenem During Continuous Renal Replacement Therapy in Critically Ill Patients,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005, 49(6):2421-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/15917542/pubmed\" id=\"15917542\" target=\"_blank\">",
"        15917542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freij BJ, McCracken GH Jr, Olsen KD, et al, \"Pharmacokinetics of Imipenem-Cilastatin in Neonates,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1985, 27(4):431-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/3859242/pubmed\" id=\"3859242\" target=\"_blank\">",
"        3859242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Overturf GD, &ldquo;Use of Imipenem-Cilastatin in Pediatrics,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):792-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/2687788 /pubmed\" id=\"2687788 \" target=\"_blank\">",
"        2687788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed MD, Kliegman RM, Yamashita TS, et al, \"Clinical Pharmacology of Imipenem and Cilastatin in Premature Infants During the First Week of Life,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1990, 34(6):1172-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/2393278/pubmed\" id=\"2393278\" target=\"_blank\">",
"        2393278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Somani P, Freimer EH, Gross ML, et al, &ldquo;Pharmacokinetics of Imipenem-Cilastatin in Patients With Renal Insufficiency Undergoing Continuous Ambulatory Peritoneal Dialysis,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1988, 32(4):530-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/3377464/pubmed\" id=\"3377464\" target=\"_blank\">",
"        3377464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taketomo CK, personal communication, September 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Gilbert DL, and Wolkin AC, \"Compatibility of Docetaxel With Selected Drugs During Simulated Y-Site Administration,\"",
"      <i>",
"       Int J Pharmaceut Compound",
"      </i>",
"      , 1999, 3(3):241-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;Melioidosis,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9370):1715-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/12767750/pubmed\" id=\"12767750\" target=\"_blank\">",
"        12767750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong VK, Wright HT Jr, Ross LA, et al, &ldquo;Imipenem/Cilastatin Treatment of Bacterial Meningitis in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1991, 10(2):122-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/39/11896/abstract-text/2062603/pubmed\" id=\"2062603\" target=\"_blank\">",
"        2062603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13375 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11896=[""].join("\n");
var outline_f11_39_11896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047840\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442616\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047832\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182043\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182027\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047843\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182093\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047836\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047842\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182095\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182092\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047846\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047831\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047830\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299512\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182036\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182039\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182052\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047839\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047829\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047845\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047847\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13375|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/36/38472?source=related_link\">",
"      Imipenem and cilastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7652?source=related_link\">",
"      Imipenem and cilastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_39_11897="What's new in infectious diseases";
var content_f11_39_11897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in infectious diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/39/11897/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11897/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11897/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11897/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/39/11897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Azithromycin and torsades de pointes",
"    </span>",
"   </p>",
"   <p>",
"    In 2013, the US Food and Drug Administration issued a warning about the risk of QT interval prolongation and potentially fatal torsades de pointes among patients taking azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients at particular risk include those with existing QT prolongation, hypokalemia, hypomagnesemia, significant bradycardia, and those receiving certain antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The warning was based on a review&nbsp;following the publication of a study that showed an increased risk of death in patients receiving azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/4\">",
"     4",
"    </a>",
"    ]. Clinicians should assess the risk of torsades de pointes when considering antibiotic treatment options for patients at risk for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/1\">",
"     1",
"    </a>",
"    ]. Other macrolides and certain non-macrolides, such as fluoroquinolones, also have the potential for prolonging the QT interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tedizolid",
"    </span>",
"   </p>",
"   <p>",
"    Tedizolid is a novel oxazolidinone drug that&nbsp;is noninferior to linezolid for the treatment of acute bacterial skin and skin structure infections in early clinical response (48 to 72 hours after initiating therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/5\">",
"     5",
"    </a>",
"    ]. Among 667 adults randomized to receive tedizolid&nbsp;or linezolid, early response rates were 79.5 and 79.4 percent, respectively; sustained treatment response rates (day 11) were 69.3 and 71.9 percent, respectively. S. aureus was isolated in more than 80 percent of patients with a positive culture; MRSA was isolated from more than 40 percent of positive cultures. In contrast to linezolid, tedizolid is administered once daily.&nbsp;The safety profiles, including hematologic toxicities, were comparable between the groups. Thus far tedizolid is not available for use in the United States and has not received approval from the US&nbsp; Food and Drug Administration.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link&amp;anchor=H703155#H703155\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\", section on 'Linezolid or tedizolid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BACTERIAL INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intravenous albumin for the prevention of hepatorenal syndrome",
"    </span>",
"   </p>",
"   <p>",
"    Several trials have suggested that, in patients with spontaneous bacterial peritonitis (SBP), the administration of intravenous albumin (1.5",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    at the time that the infection is diagnosed&nbsp;and another dose of albumin (1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    on day&nbsp;three of antibiotic treatment may improve outcomes.&nbsp;In a&nbsp;meta-analysis of four controlled trials (with a total of 288 patients), albumin infusion (in addition to antibiotics) significantly decreased the incidence of renal impairment (8 versus 31 percent) and mortality (16 versus 35 percent) compared with antibiotics alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/6\">",
"     6",
"    </a>",
"    ].&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H21#H21\">",
"     \"Hepatorenal syndrome\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     S. aureus bacteremia and bedside infectious disease consultation",
"    </span>",
"   </p>",
"   <p>",
"    Bedside infectious disease consultation for patients with S. aureus bacteremia is associated with lower rates of treatment failure, relapse, and mortality. A recent retrospective study compared bedside with telephone infectious disease consultation for management of 342 patients with S. aureus bacteremia&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/7\">",
"     7",
"    </a>",
"    ]; bedside consultation was associated with significantly lower 90-day mortality (1 percent for those who received consultation versus 8 percent for those who did not). Whenever feasible, patients with S. aureus bacteremia should have a bedside infectious disease consultation.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chlorhexidine bathing for intensive care and hematopoietic cell transplant patients",
"    </span>",
"   </p>",
"   <p>",
"    Use of antiseptic agents for patient bathing has been demonstrated to reduce the rate of hospital-acquired bloodstream infections and the risk of colonization with drug-resistant organisms. The greatest efficacy has been demonstrated with chlorhexidine gluconate, an antiseptic agent with broad-spectrum activity. Among more than 7000 patients in intensive care and&nbsp;hematopoietic cell&nbsp;transplant units randomly assigned&nbsp;to bathing with either 2 percent chlorhexidine-impregnated washcloths or nonantimicrobial washcloths for a six-month period (followed by crossover for the alternate product for the subsequent six months), chlorhexidine bathing was associated with reduction in the rate of hospital-acquired bloodstream infections by 28 percent and reduction in the rate of colonization with drug-resistant organisms by 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H3992580#H3992580\">",
"     \"General principles of infection control\", section on 'Patient bathing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fecal microbiota transplant for Clostridium difficile infection",
"    </span>",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients with Clostridium difficile (C. difficile)-associated diarrhea have recurrent disease after an initial course of antibiotic therapy. In an open label randomized controlled trial, 43 patients with recurrent C. difficile infection after at least one course of antibiotic therapy were randomly assigned to one of three treatment arms: duodenal infusion of donor feces preceded by an abbreviated regimen of vancomycin (vancomycin 500 mg four times daily for four days) and bowel lavage; a standard vancomycin regimen (vancomycin 500 mg four times daily for 14 days); or a standard vancomycin regimen with bowel lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/9\">",
"     9",
"    </a>",
"    ]. A single infusion of donor feces resulted in significantly higher rates of resolution of C. difficile-associated diarrhea without relapse at 10 weeks as compared with a standard vancomycin regimen with or without bowel lavage (81, 23, and 31 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link&amp;anchor=H11299943#H11299943\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\", section on 'Administration via nasogastric tube'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Raxibacumab for inhalation anthrax",
"    </span>",
"   </p>",
"   <p>",
"    Raxibacumab, a monoclonal antibody directed against Bacillus anthracis protective antigen, was found to be effective for the treatment and prevention of anthrax in randomized trials in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In phase 2 safety studies in humans, the levels of the antibody achieved in humans are equal to or greater than those that provide protection in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/12\">",
"     12",
"    </a>",
"    ]. In 2012, raxibacumab was approved by the US Food and Drug Administration for the treatment of inhalation anthrax (in combination with antibiotics) and for the prevention of inhalation anthrax when alternative preventive therapies are not available or are not appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A supply of raxibacumab is held in the United States Strategic National Stockpile for use by the Centers for Disease Control in the event of an anthrax emergency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link&amp;anchor=H1061471327#H1061471327\">",
"     \"Treatment of anthrax\", section on 'Raxibacumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=see_link&amp;anchor=H64397865#H64397865\">",
"     \"Prevention of anthrax\", section on 'Raxibacumab and other immunotherapeutics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recurrence of erythema migrans: reinfection or relapse?",
"    </span>",
"   </p>",
"   <p>",
"    When patients develop a second episode of erythema migrans after being treated for early Lyme disease, some clinicians have been uncertain whether this represents reinfection with a different strain of Borrelia burgdorferi or relapse of the initial infection. In a study that included 22 paired (initial and second) episodes of erythema migrans, molecular typing of the B. burgdorferi gene encoding outer surface protein C (ospC) was performed using B. burgdorferi strains that were detected in cultures of skin or blood specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/15\">",
"     15",
"    </a>",
"    ]. The ospC genotype was found to be different at each initial and second episode of erythema migrans, demonstrating that repeat episodes of erythema migrans in appropriately treated patients were due to reinfection rather than relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Reinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FUNGAL INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Amphotericin B plus flucytosine for cryptococcal meningitis",
"    </span>",
"   </p>",
"   <p>",
"    A randomized open-label trial compared three different induction therapy regimens (amphotericin B deoxycholate as monotherapy, or combined with either flucytosine or fluconazole) for cryptococcal meningitis in HIV-infected patients in Vietnam&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/16\">",
"     16",
"    </a>",
"    ]. Amphotericin B plus flucytosine resulted in decreased mortality and increased clearance rates of yeast from the cerebrospinal fluid compared with the other regimens. Mortality rates were similar for amphotericin B plus fluconazole and amphotericin B monotherapy. The superiority of combination therapy with amphotericin B plus flucytosine in this trial strongly supports the recommendation to use this regimen for induction therapy of cryptococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=see_link&amp;anchor=H5331892#H5331892\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Induction and consolidation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Outbreak of fungal central nervous system infection and septic arthritis",
"    </span>",
"   </p>",
"   <p>",
"    A multistate outbreak of fungal central nervous system infection and septic arthritis was detected in the United States in late September 2012 when patients who had received epidural injections of methylprednisolone produced at a single compounding center (New England Compounding Center) developed meningitis with or without posterior circulation stroke and patients who received intra-articular injections of the same drug developed septic arthritis (",
"    <a class=\"graphic graphic_figure graphicRef86787 \" href=\"UTD.htm?34/9/34964\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef86788 \" href=\"UTD.htm?34/35/35391\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Although early in the outbreak the majority of patients presented with meningitis, the percentage of patients presenting with epidural abscess, phlegmon, discitis, vertebral osteomyelitis, or arachnoiditis at or near the site of injection has increased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/20\">",
"     20",
"    </a>",
"    ]. The most common pathogen isolated from patients affected by the outbreak has been Exserohilum spp (",
"    <a class=\"graphic graphic_picture graphicRef86772 \" href=\"UTD.htm?37/55/38769\">",
"     picture 1",
"    </a>",
"    ), a dematiaceous (brown-black) fungus&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. Updated information about case counts, diagnosis, and management can be found at the United States Centers for Disease&nbsp;Control and Prevention's website.&nbsp;United States Centers for Disease Control and Prevention&rsquo;s website. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19321?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IMMUNOCOMPROMISED HOSTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ASCO guidelines for the outpatient management of neutropenia",
"    </span>",
"   </p>",
"   <p>",
"    In 2013, the American Society of Clinical Oncology (ASCO) published guidelines for antimicrobial prophylaxis of adult neutropenic oncology outpatients, for selection of patients with neutropenic fever who could be treated as outpatients, and treatment recommendations for outpatient management of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/22\">",
"     22",
"    </a>",
"    ]. These guidelines focus on patients who are generally considered to be at low risk for medical complications of neutropenic fever, such as patients receiving chemotherapy for solid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Combination vaccine for meningococcus and Haemophilus influenzae type b",
"    </span>",
"   </p>",
"   <p>",
"    A combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type b (MenHibrix, HibMenCY) was approved by the US Food and Drug Administration in June 2012 for infants and children 6 weeks to 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In prelicensure trials, this vaccine was safe, immunogenic, and did not interfere with immune responses to routine immunizations. In January 2013, the United States Advisory Panel on Immunization Practices began recommending HibMenCY for certain infants and toddlers at increased risk for meningococcal disease, beginning at two months of age (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. It is the first meningococcal vaccine to be recommended in the United States for use in infants younger than nine months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H937132#H937132\">",
"     \"Meningococcal vaccines\", section on 'Combination conjugate vaccine against meningococcus and Haemophilus influenzae type b'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H182642754#H182642754\">",
"     \"Meningococcal vaccines\", section on 'In infants and toddlers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tdap during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    The prevalence of pertussis in the United States has been increasing, in part because pertussis immunity after vaccination or disease wanes over time. Infants younger than three months of age are at highest risk of morbidity and mortality from this infection, and many infants contract pertussis from their mothers. Vaccination of the mother can thus significantly decrease the risk of infant exposure, and placental transfer of maternal antibodies may additionally provide a degree of passive protection to the infant for two to six months. In 2013, the United States Advisory Committee on Immunization Practices (ACIP) recommended that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, optimally between 27 and 36 weeks of gestation, regardless of prior vaccination status, to increase the likelihood of optimal protection against pertussis for both the mother and her infant during the first few months of the infant&rsquo;s life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/27\">",
"     27",
"    </a>",
"    ]. Previously, Tdap was recommended only for pregnant women who had not previously received the acellular pertussis vaccine during adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     2012-2013 seasonal influenza vaccine effectiveness",
"    </span>",
"   </p>",
"   <p>",
"    In a case-control study of 2697 individuals with acute respiratory illness enrolled between early December 2012 and mid-January 2013, the United States Centers for Disease Control and Prevention estimated that the effectiveness of the 2012-2013 seasonal influenza vaccines in preventing medically-attended influenza infections in all age groups was 56 percent (95% CI 47-63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/28\">",
"     28",
"    </a>",
"    ]. Effectiveness against influenza A was 47 percent (95% CI 35-58 percent) and against influenza B was 67 percent (95% CI 51-78 percent). However, the age-stratified effectiveness estimate against H3N2 influenza A was only 9 percent for individuals &ge;65 years of age (compared with 46 to 50 percent for individuals from 18 to 64 years of age).",
"    <br/>",
"    <br/>",
"    Given the moderate overall effectiveness of the vaccine (and poor effectiveness against H3N2 influenza A in older adults), influenza infection will occur among some individuals who received the influenza vaccine. This highlights the importance of early antiviral therapy (regardless of vaccination status), particularly for those at risk for severe or complicated influenza infection.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H205840196#H205840196\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Effectiveness for the 2012-2013 season'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tdap recommended during each pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    US Advisory Committee on Immunization Practices (ACIP) now recommends that all pregnant women receive tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, to better protect their infant against pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/27\">",
"     27",
"    </a>",
"    ]. Tdap should be administered after 20 weeks and optimally between 27 and 36 weeks, regardless of prior vaccination status. Previously, Tdap was recommended only for pregnant women who had never received the acellular pertussis vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Safety and efficacy of influenza vaccination in pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Influenza vaccination is recommended for pregnant women because both mother and fetus are at increased risk of complications related to this infection, including fetal death. In addition, maternal vaccination provides passive protection to the infant. However, concerns about vaccine safety have interfered with compliance in this patient group. The safety and efficacy of vaccination of pregnant women were confirmed in a retrospective analysis of over 100,000 pregnancies during the 2009 influenza A (H1N1) pandemic in Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/29\">",
"     29",
"    </a>",
"    ]. Vaccination during pregnancy substantially reduced the risk of a maternal influenza diagnosis (adjusted hazard ratio, 0.30) and was associated with a trend in reduction of fetal death. All women who are pregnant or will be pregnant during influenza season should receive the inactivated influenza vaccine, regardless of pregnancy trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795661#H5795661\">",
"     \"Influenza and pregnancy\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Meningococcal serogroup B vaccine",
"    </span>",
"   </p>",
"   <p>",
"    Although group B meningococcus is one of the most common serotypes causing infection, no broadly effective vaccine preparation is licensed for use to prevent infection with this serogroup [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A major challenge in the development of a vaccine has been that the serogroup B polysaccharide is a very poor immunogen in humans, probably due to the similarity of its immunochemical structure to human intracellular adhesion molecules. In January 2013, the European Commission approved a meningococcal serogroup B vaccine (Bexsero) for use in individuals over two months of age in the European Union [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/32\">",
"     32",
"    </a>",
"    ]. The vaccine includes three recombinant proteins (neisserial adhesin A, factor H binding protein, and neisserial heparin binding antigen) with outer membrane vesicles from a strain that caused an epidemic in New Zealand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H454501268#H454501268\">",
"     \"Meningococcal vaccines\", section on 'Group B meningococcus vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Meningococcal vaccination for men who have sex with men from New York City",
"    </span>",
"   </p>",
"   <p>",
"    In the fall of 2012, an outbreak of invasive meningococcal disease was detected in men who have sex with men (MSM) in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Since 2010, 14 cases have been detected, with 9 cases occurring in 2012 (as of late October). Nine of the 14 cases have been in HIV-infected men. As of late October 2012, four patients have died, three of whom were HIV-infected. Given the current outbreak, we recommend meningococcal vaccination for MSM, especially if HIV-infected, if their residence, travel, or social interactions have put them (or will put them) in close contact with other MSM from New York City since September 1, 2012 (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H2#H2\">",
"     \"Meningococcal vaccines\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H21#H21\">",
"     \"Meningococcal vaccines\", section on 'In adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H19#H19\">",
"     \"Immunizations in HIV-infected patients\", section on 'Meningococcal vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Egg-free influenza vaccine",
"    </span>",
"   </p>",
"   <p>",
"    A trivalent inactivated influenza vaccine (Optaflu), produced using cultured mammalian cells, was approved in Europe for use in adults beginning in the 2007-2008 influenza season. This same vaccine (called Flucelvax) was approved for individuals &ge;18 years of age for the 2012-2013 season by the US Food and Drug Administration in November 2012&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A second egg-free vaccine (Flublok), made using an insect virus (baculovirus) expression system and recombinant DNA technology, was approved in January 2013 by the FDA for adults aged 18 to 49 years. The efficacy and rates of serious adverse events seen with&nbsp;both egg-free&nbsp;vaccines were comparable to standard available influenza vaccines. For&nbsp;patients age 18 or older with egg allergy, we recommend administration of&nbsp;an age-appropriate,&nbsp;egg-free, trivalent inactivated influenza vaccine (TIV) rather than an egg-based inactivated vaccine. However, if the&nbsp;an egg-free&nbsp;vaccine is not readily available, immunization should proceed with egg-based vaccination with appropriate precautions (eg, observation for 30 minutes following vaccination in patients with mild allergic reactions to egg, and immunization supervised by an allergy specialist for patients with a history of severe egg allergic reactions).",
"    <br/>",
"    <br/>",
"    We recommend not using&nbsp;the egg-free vaccine in patients younger than age 18, since the",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine appears to be less immunogenic in young children and the immunogenicity of these vaccines and the rates of side effects in this population are otherwise not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H8#H8\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Alternative methods of vaccine production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H9#H9\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Options for testing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MYCOBACTERIAL INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bedaquiline and multidrug-resistant tuberculosis",
"    </span>",
"   </p>",
"   <p>",
"    Bedaquiline (Sirturo), the diarylquinoline TMC207, is an antituberculous agent with a novel mechanism of mycobacterial ATP synthase inhibition. It received accelerated approval in the United States by the Food and Drug Administration (FDA) in December 2012 for use as part of combination therapy to treat adults with multidrug-resistant pulmonary TB (MDR-TB) when other alternatives are not available. Among 440 patients with MDR-TB in two phase 2 clinical trials, those who received bedaquiline in combination with an optimized background regimen had faster and more frequent conversion to negative sputum than patients receiving an optimized background regimen only (77.6 versus 57.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A black box warning alerts that bedaquiline can cause QT prolongation. In data submitted to the FDA, death was observed more frequently among patients receiving treatment with bedaquiline than those treated with background regimens only (11.4 versus 2.5 percent). Therefore, the drug should be used only for patients who do not have other treatment options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link&amp;anchor=H3115421#H3115421\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\", section on 'New agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Linezolid and extensively drug-resistant tuberculosis",
"    </span>",
"   </p>",
"   <p>",
"    Treatment of extensively drug-resistant TB (XDR TB) should include five or more drugs to which the isolate is susceptible. Of the third-line agents to be used when resistance or drug availability precludes the use of other agents, the benefit of linezolid was illustrated in a study of 38 HIV-negative patients with refractory XDR TB in South Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients continued their current regimen and were randomized to the addition of linezolid (600 mg daily) immediately or following a two-month delay. Following sputum culture conversion or four months of treatment with linezolid, patients underwent a second randomization to either continue linezolid at 600 mg daily or reduce the dose to 300 mg daily. Sputum culture conversion was achieved among 79 percent of patients in the immediate-start group and 35 percent of patients in the delayed-start group. In both groups, culture conversion was achieved at six months of therapy among 89 percent of patients. Use of linezolid must be balanced with the considerable toxicity of long-term use and further amplification of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\", section on 'Treatment for documented XDR TB'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PARASITIC INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Three-dose intermittent preventive treatment of malaria during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    The previous recommendation for delivering Intermittent Preventive Treatment (IPTp) for malaria to pregnant women in areas of medium and high malaria transmission was a two-dose regimen. In a systematic review and meta-analysis, use of an IPTp&nbsp;regimen that&nbsp;included three or more doses,&nbsp;rather than&nbsp;a&nbsp;two-dose regimen, resulted in fewer low birth weight infants, less placental malaria, and less moderate to severe maternal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, for pregnant women who reside in areas of medium and high malaria transmission, we recommend treatment with three doses of sulfadoxine pyrimethamine as Intermittent Preventive Treatment (IPTp), rather than two doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and prevention of malaria in pregnancy\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TICK-BORNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Borrelia miyamotoi infection",
"    </span>",
"   </p>",
"   <p>",
"    Borrelia miyamotoi, a species in the same taxonomic group as the agents of relapsing fever, has been found in some tick vectors and rodent reservoirs for Lyme disease agents in North America, Europe, and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/41\">",
"     41",
"    </a>",
"    ]. Several reports have described clinical syndromes in patients with evidence of B. miyamotoi infection. Serologic testing on archived samples&nbsp;from individuals in Lyme disease-endemic regions in the United States found the seroprevalence of antibodies against B. miyamotoi to be 21.0 percent in patients who presented with a virus-like illness in the late spring or summer, 3.2 percent in patients with possible Lyme disease, and 1.0 percent in healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/42\">",
"     42",
"    </a>",
"    ]. One patient with recent B. miyamotoi seroconversion had multiple systemic symptoms including arthralgias and inguinal adenopathy but&nbsp;no&nbsp;erythema migrans and no laboratory evidence of human granulocytic anaplasmosis coinfection. B. miyamotoi was detected in the cerebrospinal fluid of a woman with follicular lymphoma in the northeastern United States who presented with progressive mental decline over four months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/43\">",
"     43",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Additional study is necessary to further characterize the clinical syndromes caused by B. miyamotoi and to determine if this species can cause relapsing fever, an illness similar to Lyme disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distinct syndromes.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15033?source=see_link&amp;anchor=H343465099#H343465099\">",
"     \"Clinical features, diagnosis, and management of relapsing fever\", section on 'Borrelia miyamotoi infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     VIRAL INFECTIONS, NON-HIV",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Novel avian H7N9 influenza infection in China",
"    </span>",
"   </p>",
"   <p>",
"    In late March and early April 2013, over 40 human cases (including fatal cases) of novel H7N9 infection in eastern China&nbsp;were reported to the World Health Organization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].&nbsp;Patients have presented with respiratory tract infections, which have progressed to severe pneumonia.",
"    <br/>",
"    <br/>",
"    These are the first cases of H7N9 influenza&nbsp;infection to be detected in humans. The virus appears to have derived from reassortment of three avian influenza viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/49\">",
"     49",
"    </a>",
"    ]. Several of the affected patients had exposures to poultry before becoming ill [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. To date, there is no evidence of human-to-human transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link&amp;anchor=H2433338#H2433338\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\", section on 'Avian influenza H7N9 in China'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Herpes zoster and tumor necrosis factor-alpha inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    There have been conflicting data regarding whether tumor necrosis factor (TNF)-alpha inhibitors confer a greater risk of herpes zoster compared with other therapies in patients with underlying autoimmune disease. The largest study to address this issue was a multicenter cohort study, which compared the incidence of herpes zoster in patients with rheumatoid arthritis or another autoimmune disease who initiated a TNF-alpha inhibitor or a nonbiologic disease-modifying antirheumatic drug (DMARD) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/53\">",
"     53",
"    </a>",
"    ].&nbsp;Risk for herpes zoster was not increased in patients who initiated a TNF-alpha inhibitor compared with patients initiating nonbiologic DMARDs. The study also showed that baseline use of glucocorticoids at a dose of &ge;10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day prednisone equivalents was associated with an increased risk of herpes zoster, as seen in previous studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link&amp;anchor=H12#H12\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Herpes zoster'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\", section on 'Autoimmune disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Narcolepsy following adjuvanted 2009 pandemic H1N1 influenza vaccination",
"    </span>",
"   </p>",
"   <p>",
"    Individuals in several countries in Europe have developed narcolepsy after receiving Pandemrix, an AS03 (oil-in-water emulsion)-adjuvanted 2009 pandemic H1N1 influenza vaccine. Pandemrix was used in certain countries during the 2009-2010 H1N1 influenza pandemic, but it was not used in the United States. This association was first reported among&nbsp;children and adolescents in Finland and Sweden in 2010&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/54\">",
"     54",
"    </a>",
"    ]. These findings have been confirmed in a subsequent large retrospective database review that included six countries in Europe over a 10-year period; increased narcolepsy rates were observed in Sweden, Finland, and Denmark after the initiation of Pandemrix vaccination campaigns, primarily in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/55\">",
"     55",
"    </a>",
"    ].&nbsp;An increased risk of narcolepsy was also observed in children and adolescents who received Pandemrix&nbsp;in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H592844613#H592844613\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Narcolepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     IV acyclovir shortage in the United States",
"    </span>",
"   </p>",
"   <p>",
"    As of November 2012, there is a shortage of intravenous (IV) acyclovir in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. IV acyclovir, if available, is the drug of choice for the following indications: neonates with proven herpes simplex virus (HSV) disease, pregnant women with HSV or varicella-zoster virus infection, and individuals with herpes simplex encephalitis; during this shortage, IV acyclovir should be reserved for patients with these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11897/abstract/59\">",
"     59",
"    </a>",
"    ]. Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm#acyclovir\">",
"     web site",
"    </a>",
"    for the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm\">",
"     US Food and Drug Administration",
"    </a>",
"    for information about the availability of IV acyclovir. Treatment recommendations for the use of alternative antiviral agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     US Food and Drug Administration. Azithromycin (Zithromax or Zmax): Drug safety communication - risk of potentially fatal heart rhythms. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343350.htm?source=govdelivery (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Zmax (azithromycin extended release) for oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262866.htm (Accessed on May 18, 2012).",
"    </li>",
"    <li>",
"     ZITHROMAX (azithromycin tablets) and(azithromycin for oral suspension) - prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/4\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/5\">",
"      Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/6\">",
"      Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/7\">",
"      Forsblom E, Ruotsalainen E, Ollgren J, J&auml;rvinen A. Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus Bacteremia. Clin Infect Dis 2013; 56:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/8\">",
"      Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/9\">",
"      van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/10\">",
"      Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/11\">",
"      Barochia AV, Cui X, Sun J, et al. Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis 2012; 205:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/12\">",
"      Nabel GJ. Protecting against future shock--inhalational anthrax. N Engl J Med 2009; 361:191.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release. FDA approves raxibacumab to treat inhalational anthrax. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     Anti-Infective Drugs Advisory Committee Meeting - 02 November 2012. Human Genome Sciences, Inc. Briefing Document, Raxibacumab - ",
"Treatment of Inhalational Anthrax. BLA 125349. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM326185.pdf (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/15\">",
"      Nadelman RB, Hanincov&aacute; K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012; 367:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/16\">",
"      Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/17\">",
"      Perfect JR. Efficiently killing a sugar-coated yeast. N Engl J Med 2013; 368:1354.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Multi-state meningitis outbreak. file://www.cdc.gov/hai/outbreaks/meningitis.html (Accessed on January 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:839.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Health Alert Network. Update: multistate outbreak of fungal meningitis and other infections associated with contaminated steroid medication. file://emergency.cdc.gov/HAN/han00335.asp (Accessed on November 22, 2012).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. Warnings, cases expand in fungal meningitis outbreak. file://www.cidrap.umn.edu/cidrap/content/other/news/oct1612fungusbr.html (Accessed on October 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/22\">",
"      Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. News &amp; Events. FDA approves new combination vaccine that protects children against two bacterial diseases. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Menhibrix&amp;utm_content=1 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     GSK receives FDA approval for MenHibrix. file://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1134059.htm (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/26\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep 2013; 62:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/29\">",
"      H&aring;berg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/30\">",
"      Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50 Suppl 2:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/31\">",
"      Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511.",
"     </a>",
"    </li>",
"    <li>",
"     Novartis media releases. Novartis receives EU approval for Bexsero, first vaccine to prevent the leading cause of life-threatening meningitis across Europe. file://www.novartis.com/newsroom/media-releases/en/2013/1672036.shtml (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. file://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     Commonwealth of Masschusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/37\">",
"      Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/38\">",
"      Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/39\">",
"      Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/40\">",
"      Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 2013; 309:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/41\">",
"      Barbour AG, Bunikis J, Travinsky B, et al. Niche partitioning of Borrelia burgdorferi and Borrelia miyamotoi in the same tick vector and mammalian reservoir species. Am J Trop Med Hyg 2009; 81:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/42\">",
"      Krause PJ, Narasimhan S, Wormser GP, et al. Human Borrelia miyamotoi infection in the United States. N Engl J Med 2013; 368:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/43\">",
"      Gugliota JL, Goethert HK, Berardi VP, Telford SR III. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. H7N9 avian influenza human infections in China. file://www.who.int/csr/don/2013_04_01/en/index.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. Human infection with influenza A(H7N9) virus in China - update. file://www.who.int/csr/don/2013_04_04/en/index.html (Accessed on April 04, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. Human infection with influenza A(H7N9) in China &ndash; update. file://www.who.int/csr/don/2013_04_03/en/index.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. China reports more H7N9 cases, deaths; virus may be in pigeons. file://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/apr0413china.html (Accessed on April 05, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Global alert and response. Human infection with influenza A(H7N9) virus in China - update. file://www.who.int/csr/don/2013_04_12/en/index.html (Accessed on April 12, 2013).",
"    </li>",
"    <li>",
"     Nature. Novel bird flu kills two in China. file://www.nature.com/news/novel-bird-flu-kills-two-in-china-1.12728 (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. China reports 4 more H7N9 infections. file://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/apr0213china_(2)br.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     Center for Infectious Disease Research &amp; Policy. China reports three H7N9 infections, two fatal. file://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/ap0113chinabr.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Frequently asked questions on human infection with A(H7N9) avian influenza virus, China. file://www.who.int/influenza/human_animal_interface/faq_H7N9/en/index.html (Accessed on April 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/53\">",
"      Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309:887.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination, 21 April 2011. file://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/index.html (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/55\">",
"      Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11897/abstract/56\">",
"      Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online. Antiviral recommendations for herpes simplex virus (HSV) and varicella zoster virus (vzv) infections in hospitalized pediatric patients during the intravenous acyclovir shortage. file://aapredbook.aappublications.org/site/news/acyclovir.xhtml (Accessed on December 04, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8358 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11897=[""].join("\n");
var outline_f11_39_11897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ANTIMICROBIAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Azithromycin and torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tedizolid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BACTERIAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intravenous albumin for the prevention of hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      S. aureus bacteremia and bedside infectious disease consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chlorhexidine bathing for intensive care and hematopoietic cell transplant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fecal microbiota transplant for Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Raxibacumab for inhalation anthrax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recurrence of erythema migrans: reinfection or relapse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FUNGAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Amphotericin B plus flucytosine for cryptococcal meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Outbreak of fungal central nervous system infection and septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IMMUNOCOMPROMISED HOSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASCO guidelines for the outpatient management of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Combination vaccine for meningococcus and Haemophilus influenzae type b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tdap during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      2012-2013 seasonal influenza vaccine effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tdap recommended during each pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Safety and efficacy of influenza vaccination in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Meningococcal serogroup B vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Meningococcal vaccination for men who have sex with men from New York City",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Egg-free influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MYCOBACTERIAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bedaquiline and multidrug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Linezolid and extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PARASITIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Three-dose intermittent preventive treatment of malaria during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TICK-BORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Borrelia miyamotoi infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      VIRAL INFECTIONS, NON-HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Novel avian H7N9 influenza infection in China",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Herpes zoster and tumor necrosis factor-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Narcolepsy following adjuvanted 2009 pandemic H1N1 influenza vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      IV acyclovir shortage in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8358|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/9/34964\" title=\"figure 1\">",
"      Map of states with recalled methylprednisolone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8358|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/55/38769\" title=\"picture 1\">",
"      Exserohilum rostratum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/35/35391\" title=\"table 1\">",
"      Healthcare facilities with recalled methylprednisolone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 2\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 3\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15033?source=related_link\">",
"      Clinical features, diagnosis, and management of relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=related_link\">",
"      Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19321?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=related_link\">",
"      Prevention of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=related_link\">",
"      Treatment of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_39_11898="Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants";
var content_f11_39_11898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/39/11898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11898/contributors\">",
"     Ronald J Wong, BA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11898/contributors\">",
"     Vinod K Bhutani, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/39/11898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11898/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/39/11898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/39/11898/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/39/11898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all newborn infants develop a total serum or plasma bilirubin (TB) level greater than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    which is the upper limit of normal for adults. As TB increases, it produces neonatal jaundice, the yellowish discoloration of the skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sclerae caused by bilirubin deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Jaundice'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperbilirubinemia in infants &ge;35 weeks gestation is defined as a TB &gt;95th percentile for hours of age on the Bhutani nomogram [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2\">",
"     2",
"    </a>",
"    ]. Hyperbilirubinemia with a TB &gt;25 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (428 to 513",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is associated with an increased risk for bilirubin-induced neurologic dysfunction (BIND) (",
"    <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"     figure 1",
"    </a>",
"    ), which occurs when bilirubin crosses the blood-brain barrier and binds to brain tissue. The term \"acute bilirubin encephalopathy\" (ABE) is used to describe the acute manifestations of BIND, while the term \"kernicterus\" is used to describe the chronic and permanent sequelae of BIND.",
"   </p>",
"   <p>",
"    Appropriate intervention is important to consider in every infant with severe hyperbilirubinemia. However, even if these infants are adequately treated, long-term neurologic sequelae (kernicterus) can sometimes develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of neonatal unconjugated hyperbilirubinemia is reviewed here. The pathogenesis, etiology, clinical manifestations, and treatment of hyperbilirubinemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two advances in medical care had a significant impact on the need for treatment and the way in which hyperbilirubinemia is managed. The administration of Rh (D) immunoglobulin to Rh-negative mothers in the late 1960s dramatically decreased the incidence of neonatal Rh isoimmune hemolytic disease. At about the same time, the introduction of phototherapy in the United States significantly reduced the need for exchange transfusions and the risk of severe hyperbilirubinemia. Thus, the risk of kernicterus was reduced from its peak in the 1950s through the 1970s. Nevertheless, isolated cases of kernicterus, a preventable condition, continue to be reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A root-cause analysis of factors contributing to kernicterus identified the following potentially correctable factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Discharge before 48 hours after birth without appropriate follow-up",
"     </li>",
"     <li>",
"      Failure to measure the total serum or plasma bilirubin (TB) concentration in an infant with jaundice within 24 hours of age",
"     </li>",
"     <li>",
"      Failure to recognize risk factors for hyperbilirubinemia",
"     </li>",
"     <li>",
"      Lack of concern regarding the presence of jaundice",
"     </li>",
"     <li>",
"      Delayed measurement of TB in infants with severe jaundice",
"     </li>",
"     <li>",
"      Delayed initiation of phototherapy in infants with elevated TB",
"     </li>",
"     <li>",
"      Lack of response to parental concerns regarding jaundice, lethargy, or poor feeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the increase in the prevalence of breastfeeding combined with early hospital discharge has unmasked a previously unappreciated potential for marked hyperbilirubinemia among a select and unfortunate few, the basis of which might be partly genetic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings in the above analysis were supported in reports from the Pilot Kernicterus Registry of neonates who were readmitted for severe hyperbilirubinemia, median TB of 39",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (667",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    with a range of 20.7 to 59.9 mg dL (354 to 1024",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    within the first seven days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/6\">",
"     6",
"    </a>",
"    ]. No specific TB threshold coincided with the onset of acute bilirubin encephalopathy (ABE). Analysis of these voluntarily reported cases suggested that kernicterus could have been prevented if a systematic approach were in place that identified and treated infants at risk for severe hyperbilirubinemia.",
"   </p>",
"   <p>",
"    The correctable factors that mainly contributed to severe hyperbilirubinemia in the initial report of 61 infants were [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to arrange appropriate and timely follow-up or keep follow-up appointments &ndash; 47 infants",
"     </li>",
"     <li>",
"      Failure of the clinical staff to document either the presence or absence of jaundice &ndash; 25 infants",
"     </li>",
"     <li>",
"      Failure to recognize that visual assessment is not a reliable measure of TB &ndash; 20 infants",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYSTEMATIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based in part upon the above data, the American Academy of Pediatrics (AAP) and the United Kingdom&rsquo;s National Institute of Health and Clinical Excellence (NICE) developed clinical practice guidelines to identify, evaluate, and treat term and late preterm infants at risk for severe hyperbilirubinemia (",
"    <a class=\"external\" href=\"file://www.nice.org.uk/nicemedia/live/12986/48679/48679.pdf\">",
"     NICE guidelines",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ]. A systematic approach based on the AAP guideline is presented in the following discussion. It is built upon two key elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal clinical assessment for the presence of jaundice and risk factors for severe hyperbilirubinemia (",
"      <a class=\"graphic graphic_table graphicRef64584 \" href=\"UTD.htm?23/29/24028\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Appropriate follow-up based upon risk assessment and the infant's age at the time of discharge",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Instituting such an approach decreases the prevalence of severe hyperbilirubinemia. This was illustrated in a retrospective review of 101,272 infants cared for in 18 nurseries before and after a bilirubin newborn screening program was established [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/9\">",
"     9",
"    </a>",
"    ]. The prevalence of severe hyperbilirubinemia (total serum or plasma bilirubin (TB) &gt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [342",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    decreased from 1.2 to 0.7 percent, which suggests that universal screening might have lead to an increase in early intervention, thus preventing hyperbilirubinemia. The rate of readmission for jaundice also decreased from 0.5 to 0.4 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Which infants require evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision on which infants require measurement of TB or transcutaneous bilirubin (TcB) is dependent on clinical findings of jaundice and risk factors for hyperbilirubinemia, including whether the infant is breast- or formula-fed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;All term and late preterm infants should be routinely assessed for the presence of jaundice every 8 to 12 hours while in the hospital. Infants who are jaundiced before 24 hours of life are at increased risk for severe hyperbilirubinemia, often due to isoimmune hemolytic disease. In these infants, a TB or TcB measurement should be performed. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Total serum or plasma bilirubin (TB)'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Transcutaneous bilirubin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A TB or TcB also should be measured in infants &gt;24 hours of age when jaundice appears excessive for age (eg, jaundice below the level of the umbilicus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Jaundice'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of TB or TcB in all infants before discharge will help to identify those who are, or are not, at risk for the development of severe hyperbilirubinemia. TB can be measured at the time of the newborn screening for metabolic disorders, thus obviating the need for an additional blood sample, although there are additional costs involved.",
"   </p>",
"   <p>",
"    Visual assessment is not as reliable as measurement of TB to detect significant hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As a result, in our practice, universal screening includes bilirubin testing prior to discharge.",
"   </p>",
"   <p>",
"    TB and TcB measurements are interpreted according to the infant's age based upon normative data (",
"    <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"     figure 1",
"    </a>",
"    ). Further evaluation based upon these data is discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Total serum or plasma bilirubin (TB)'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Transcutaneous bilirubin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discharge, every infant should be assessed for the risk of subsequent severe hyperbilirubinemia (",
"    <a class=\"graphic graphic_table graphicRef64584 \" href=\"UTD.htm?23/29/24028\">",
"     table 1",
"    </a>",
"    ). Prediction of severe hyperbilirubinemia is based upon a bilirubin measurement (TB or TcB)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    assessment of risk factors for hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TB or TcB values are compared to age-specific percentile-based nomograms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2,12\">",
"     2,12",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"     figure 1",
"    </a>",
"    ). TcB values &gt;75th percentile need to be confirmed by TB measurements, because TcB values often underestimate TB.",
"   </p>",
"   <p>",
"    Infants, particularly if they are &le;38 weeks of gestation, with TB values &ge;95th percentile, are at high risk for the development of severe hyperbilirubinemia that can evolve to BIND [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These infants require additional evaluation, including monitoring of TB levels and possibly therapy to prevent or treat severe hyperbilirubinemia.",
"   </p>",
"   <p>",
"    The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Total serum or plasma bilirubin (TB)'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Transcutaneous bilirubin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Additional evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, low-risk TB levels do not completely eliminate subsequent significant hyperbilirubinemia, which may lead to readmission. This was illustrated in an Israeli study of 25,439 neonates, in which 0.6 percent of the cohort was readmitted for hyperbilirubinemia (mean TB = 18.7). Of these 143 patients, 6 had predischarge TB in the low-risk zone and 46 in the intermediate-low-risk zone. These results demonstrate the effectiveness of predischarge bilirubin screening, but also serve as a reminder of the importance of timely follow-up after discharge. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Breastfed infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because TB values are higher in breast- than in formula-fed infants, evaluating breastfeeding and providing counseling should be performed before discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\", section on 'Breastfeeding failure jaundice'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of breastfeeding are well described, and mothers should be encouraged to breastfeed their infants. If breastfeeding is interrupted, mothers should continue to pump and store their breast milk to ensure stimulation for adequate milk production. Breastfeeding should be resumed as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of frequent feedings (at least 8 to 12 times per day for the first several days) should be emphasized. Lactation consultants (during hospitalization) and home visits by a nurse (after discharge) may be helpful.",
"   </p>",
"   <p>",
"    Although any infant who is feeding poorly and with poor weight gain requires increased surveillance for jaundice, late preterm infants (35 to 37 weeks gestation) are at greater risk to receive inadequate fluid and nutrition, and thereby require increased surveillance to initiate timely intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=see_link\">",
"     \"Late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Universal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal bilirubin screening before discharge has been recommended by an expert panel of neonatologists and pediatricians to identify infants at high risk for the development of severe hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In our practice, universal bilirubin screening is performed at the time of routine metabolic screening in all infants prior to discharge.",
"   </p>",
"   <p>",
"    Large cohort studies have shown that universal screening has reduced the incidence of severe hyperbilirubinemia as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of infants (gestational age &gt;35 weeks) born between 1995 and 2007, the incidence of severe hyperbilirubinemia, defined as TB exceeding the level of the AAP exchange transfusion guideline, was lower in infants born at facilities with universal bilirubin screening compared to those born at facilities without universal screening (0.17 versus 0.45 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/15\">",
"       15",
"      </a>",
"      ]. Multivariate logistic regression analysis demonstrated a universal screening compared to no screening reduced the risk of severe hyperbilirubinemia (odds ratio [OR] 0.28, 95% confidence interval [CI] 0.2-0.4) and the risk of TB exceeding a level of 25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (428",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      (OR 0.22, 95% CI 0.11-0.48) or TcB (OR 0.25, 95% CI 0.12-0.53). There was an increased incidence of TB between 15 and 19.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (257 to 340",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in the universal screening group. However, this may be in part due to the decreased incidence of more severe hyperbilirubinemia because of earlier identification and treatment of hyperbilirubinemia.",
"     </li>",
"     <li>",
"      In a second multicenter study, the initiation of universal predischarge neonatal bilirubin screening reduced the incidence of TB between 25 to 29.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (428 to 511",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      from 43 to 27 per 100,000 live births and the incidence of TB &ge;30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (513",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      from 9 to 3 per 100,000 live births [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acceptance of a universal screening performed, however, has been limited because of concerns about the cost and the need for additional blood sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/17\">",
"     17",
"    </a>",
"    ]. This was illustrated by the first study, as only 10.6 percent of the 358,086 infants were born at facilities with universal bilirubin screening [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/15\">",
"     15",
"    </a>",
"    ]. TcB for universal screening has been suggested because it decreases the need for phlebotomy and reduces laboratory costs, and appears to be as effective as TB as a screening tool in detecting severe hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/12,15,18,19\">",
"     12,15,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Transcutaneous bilirubin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     USPSTF statement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force (USPSTF) concluded data were insufficient to recommend universal bilirubin screening to prevent chronic bilirubin encephalopathy (kernicterus) based upon a systematic review of the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/20\">",
"     20",
"    </a>",
"    ]. This conclusion was based upon the following [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lack of any known screening test that reliably identifies all infants at risk for kernicterus",
"     </li>",
"     <li>",
"      Insufficient data that reducing elevated TB prevents kernicterus",
"     </li>",
"     <li>",
"      Insufficient data on the potential harm of screening and phototherapy, and the known significant morbidity of exchange transfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The USPSTF acknowledged that the lack of evidence is primarily based upon the rarity of kernicterus, which makes it impossible to directly evaluate whether any intervention affects the incidence of kernicterus. As a result, severe hyperbilirubinemia has been used as a surrogate outcome because of its strong association with kernicterus. However, in the USPSTF report, it was concluded that a bilirubin level was an imperfect surrogate because of reported cases of infants with extremely high levels of bilirubin that did not result in kernicterus or kernicterus without documented high levels of bilirubin.",
"   </p>",
"   <p>",
"    In a commentary, several experts in the field (including one of the authors of this review) agreed with the USPSTF that the evidence recommending universal screening was limited, and it was unlikely that adequate data would be obtained to resolve this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/22\">",
"     22",
"    </a>",
"    ]. Nevertheless, this group recommended universal bilirubin screening based upon published case reports and their own clinical experience that kernicterus could be avoided with early identification and intervention to prevent severe hyperbilirubinemia. They concluded that universal bilirubin screening combined with risk assessment is an easily implemented systems approach that identifies infants at risk for severe hyperbilirubinemia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Background'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although not stated explicitly in the commentary, this position accepts that severe hyperbilirubinemia is an appropriate clinical surrogate for kernicterus, which is the current basis of the management of hyperbilirubinemia as recommended by the AAP. This is in contrast to the USPSTF position that data are insufficient to support substituting severe hyperbilirubinemia for kernicterus as the clinical outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Selective screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to universal bilirubin testing is selective screening in which the need for bilirubin testing is determined by the presence of clinical risk factors (",
"    <a class=\"graphic graphic_table graphicRef64584 \" href=\"UTD.htm?23/29/24028\">",
"     table 1",
"    </a>",
"    ). This approach also accepts that severe hyperbilirubinemia is an acceptable clinical surrogate for kernicterus.",
"   </p>",
"   <p>",
"    The risk for severe hyperbilirubinemia increases with the number of risk factors; however, the predictability of individual risk factors alone is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/23\">",
"     23",
"    </a>",
"    ]. The clinician caring for a newborn infant should be aware of the different risk factors and, if risk factors are present, the clinician should decide on the merits of predischarge bilirubin testing. In addition, earlier follow-up appointments should be arranged for infants at risk for hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comparison of approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies that have compared risk-assessment strategies to screen for significant neonatal hyperbilirubinemia found that the most accurate prediction of hyperbilirubinemia was the combination of a predischarge TB and clinical risk assessment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 823 term and late preterm infants, a predischarge TB and clinical risk assessment were comparable in predicting hyperbilirubinemia, defined as TB that exceeded or was within 1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [17",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      of the hour-specific phototherapy treatment threshold recommended by the AAP [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/24\">",
"       24",
"      </a>",
"      ]. Combining clinical risk factors with a predischarge TB improved the overall predictive accuracy compared to clinical risk assessment or TB alone. Gestational age, however, was the only clinical risk factor that, when added to the predischarge TB, resulted in an improved predictive accuracy.",
"     </li>",
"     <li>",
"      In a retrospective review of 996 infants who had predischarge and postdischarge TB, predischarge TB alone compared to a mathematical clinical risk scoring model predicted more accurately whether post-discharge TB would be &gt;95th percentile [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another retrospective study, combining multiple clinical risk factors with TB, which were measured within the first 48 hours of life, improved prediction of hyperbilirubinemia compared to TB levels alone [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of whether universal or selective bilirubin screening is performed, appropriate follow-up after discharge is essential, particularly with the advent of earlier discharge of infants and their mothers over the last decade. However, the ability of families of newborn infants to keep timely outpatient clinic appointments has been challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to discharge, a risk assessment for severe hyperbilirubinemia should be performed that guides the timing of the initial follow-up appointment (",
"    <a class=\"graphic graphic_table graphicRef64584 \" href=\"UTD.htm?23/29/24028\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At the time of discharge, appropriate follow-up is arranged, information and written guidelines about jaundice are provided to the parents, and instructions are given to the family on when and whom to contact for medical issues (eg, jaundice and adequacy of feeding) prior to their appointment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of the follow-up appointment depends on the age of the patient at discharge and whether risk factors for hyperbilirubinemia are present (",
"    <a class=\"graphic graphic_table graphicRef65147 \" href=\"UTD.htm?7/58/8107\">",
"     table 2",
"    </a>",
"    ). TB concentrations typically peak between 72 and 96 hours of age in Caucasian and African-American infants and longer in others (eg, Asian and preterm infants) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. Infants who are discharged prior to the anticipated peak TB require follow-up during this peak period to assess for jaundice and decide whether bilirubin measurement is needed.",
"   </p>",
"   <p>",
"    Infants who are discharged prior to 72 hours should be seen within two days of discharge, and evaluated for jaundice and the need for additional bilirubin measurements. Any infant with many risk factors might need to be seen within 24 hours, whereas one discharged with few or no risk factors can be seen after a longer interval. This question usually arises when infants are discharged on a Thursday or a Friday. Under these circumstances, clinicians should use their clinical judgment. If, on Thursday or Friday, you are discharging a formula-fed infant with a gestational age of 41 weeks who shows no sign of jaundice, it is acceptable to schedule that infant for a follow-up visit on the following Monday or Tuesday. On the other hand, if you are discharging a breastfed infant with a gestational age of 36 weeks of a primiparous mother, that infant must be seen within two days of discharge (regardless of weekends or holidays). The reasons for the follow-up decision should be documented in the chart.",
"   </p>",
"   <p>",
"    In general, the younger the patient age at the time of discharge, the earlier that follow-up is required [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Discharged less than 24 hours of age, follow-up by 72 hours of age",
"     </li>",
"     <li>",
"      Discharged between 24 and 47.9 hours of age, follow-up by 96 hours of age",
"     </li>",
"     <li>",
"      Discharged between 48 and 72 hours of age, follow-up by 120 hours of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Earlier follow-up is required if the patient has risk factors for hyperbilirubinemia.",
"   </p>",
"   <p>",
"    If appropriate follow-up cannot be arranged, discharge should be delayed until follow-up can be ensured or the period of greatest risk for hyperbilirubinemia has passed (72 to 96 hours of age). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the follow-up appointment, the infant's weight and percent change from birth weight, adequacy of intake, pattern of voiding and stooling, and the presence or absence of jaundice are assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ]. Clinical judgment based upon the infant's appearance and the interval medical history is used to determine the need for bilirubin measurement.",
"   </p>",
"   <p>",
"    Care of the breastfed infant with weight loss is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link&amp;anchor=H19#H19\">",
"     \"Initiation of breastfeeding\", section on 'Weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TOTAL SERUM OR PLASMA BILIRUBIN (TB)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    bilirubin (TB) is compared to an age-specific, percentile-based nomogram developed from a racially diverse population of newborn infants born in Philadelphia, referred to as the Bhutani nomogram (",
"    <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2\">",
"     2",
"    </a>",
"    ]&nbsp;. In this group of infants with a 60 percent rate of breastfeeding, 95th percentile values for TB were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (137",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      at 24 hours of age",
"     </li>",
"     <li>",
"      10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (171",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      at 36 hours of age",
"     </li>",
"     <li>",
"      12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (205",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      at 48 hours of age",
"     </li>",
"     <li>",
"      16",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (274",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      at 72 hours of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants with hour-specific values &ge;95th percentile are at increased risk for the development of severe hyperbilirubinemia that can evolve to bilirubin-induced neurologic dysfunction (BIND). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic intervention, usually phototherapy, is initiated to prevent development of severe hyperbilirubinemia and BIND based upon threshold TB values, above the 95th percentile, and the presence of risk factors for BIND (",
"    <a class=\"graphic graphic_figure graphicRef56490 \" href=\"UTD.htm?27/51/28464\">",
"     figure 2",
"    </a>",
"    ). The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Phototherapy indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with TB &gt;95th percentile, subsequent TB measurement is needed to direct clinical care. Additional evaluation may determine an underlying pathologic cause that may be amendable to treatment or require earlier intervention. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Additional evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB values vary substantially among institutions because of differences in racial composition, hemolytic conditions, or breastfeeding practices. This was illustrated in a multinational study of nine centers located in four countries that compared TB values of newborn infants. TB values at 30 hours of life were evaluated using the Bhutani nomogram [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2\">",
"     2",
"    </a>",
"    ]. The proportion of infants (&ge;35 weeks gestation) with TB &ge;95th percentile at 30 hours of age varied as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Five and 8 percent from two centers in Hong Kong, China",
"     </li>",
"     <li>",
"      Eight and 21 percent from two centers in Jerusalem, Israel",
"     </li>",
"     <li>",
"      Thirty-nine percent from a center in Kobe, Japan",
"     </li>",
"     <li>",
"      Results varied among four centers in the United States: 6 percent (Cleveland, OH), 9 percent (Providence, RI), 10 percent (Stanford, CA), and 16 percent (Philadelphia, PA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also variations in the incidence of severe hyperbilirubinemia (TB &gt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [342",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    In studies of term or late preterm infants from a large Northern California health maintenance organization, the following incidences of severe and hyperbilirubinemia at different TB values were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/13,28\">",
"     13,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TB &gt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (342",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; 2.00 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      TB &gt;25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (428",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; 0.14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      TB &gt;30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (513",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; 0.01 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a Danish population-based study, the incidence of \"extreme\" hyperbilirubinemia (defined as a level greater than 22",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 376",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    between 2000 and 2001 was 0.03 percent of live births at term or late preterm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Methods to measure bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two main methods are used to measure TB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chemical laboratory analyzers",
"    </span>",
"    &nbsp;&mdash;&nbsp;These analyzers used in core laboratories directly measure the TB concentration in whole, serum, or plasma samples via a chemical reaction (diazo method) or spectrophotometrically. Core laboratory bilirubin measurements provide a gold standard for bilirubin determination and are used, in general, to evaluate other methods of bilirubin measurement. These analyzers usually require a venous blood sample that can be painful and difficult to obtain in the neonate. High inter-laboratory and -instrument variability in TB measurements have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age-specific percentile-based nomogram in general clinical use and used in the AAP practice guideline is based upon TB measurements performed by chemical laboratory analyzers utilizing the diazo method [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Nonchemical photometric devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;These point-of-care devices measure bilirubin concentrations spectrophotometrically and require minimal blood volumes (eg, capillary sample by heelstick). Many of these devices are also blood gas analyzers so that several analyses (eg, pH, PaO",
"    <sub>",
"     2",
"    </sub>",
"    , and levels of sodium and calcium) may be measured on a single sample.",
"   </p>",
"   <p>",
"    Measurements utilizing nonchemical photometric devices closely correlate with the standard set by the chemical laboratory analyzers. However, at TB levels &gt;14.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (250",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], these devices may underestimate the TB, and values at these bilirubin concentrations should be confirmed with standard laboratory methods [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/32\">",
"     32",
"    </a>",
"    ]. In circumstances when TB is approaching or exceeds the 95th percentile, therapy should be initiated while awaiting confirmatory results from the core chemical laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TRANSCUTANEOUS BILIRUBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcutaneous bilirubin (TcB) measurement devices use multiwavelength spectral reflectance from the skin surface and can be used to estimate total serum or plasma bilirubin (TB), and, thus, avoid blood sampling. However, TcB measurements are not reliable in infants undergoing phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, controversy still exists as to whether TcB testing is affected by skin pigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/18,19,34\">",
"     18,19,34",
"    </a>",
"    ]. As a result, TcB measurements may be limited in these neonates (ie, infants treated with phototherapy, or darkly skinned), as the magnitude of hyperbilirubinemia cannot be accurately ascertained.",
"   </p>",
"   <p>",
"    In several reports of racially and ethnically diverse groups of term and late preterm newborns, a close correlation between TcB and TB measurements was demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/19,35\">",
"     19,35",
"    </a>",
"    ]. However, at high levels of TB (&lt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [257",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    TcB measurements underestimate TB and need to be confirmed by standard laboratory methods [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/32,36-38\">",
"     32,36-38",
"    </a>",
"    ]. As a result, TcB can replace TB in most circumstances when TB is &lt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (257",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8,32\">",
"     8,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TcB nomograms have been developed from across different ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/12,39-45\">",
"     12,39-45",
"    </a>",
"    ]. A systematic review based upon four studies that constructed TcB nomograms from predominately Caucasian, Thai, or Hispanic populations reported TcB nomogram values varied among the ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/46\">",
"     46",
"    </a>",
"    ]. Peak TcB levels occurred earliest in Thai neonates, latest in Hispanic neonates, and in-between in the Thai and Hispanic infants for the primarily Caucasian populations in the North American and European study. Although, genetic differences is one explanation for the variation in TcB nomograms, differences in study designs (eg, enrollment criteria, equipment, and frequency of other risk factors [breastfeeding versus formula feeding]) may have contributed to the differences in the results.",
"   </p>",
"   <p>",
"    In one study from the United States of 3984 healthy newborn infants (gestational age &ge;35 weeks) who were predominantly breastfed and from a Caucasian ethnicity, a nomogram for TcB measurements was developed from TcB values obtained every 6 hours during the first 96 hours-of-life using the Draeger Air-Shields TcB meter (model JM-103) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/12\">",
"     12",
"    </a>",
"    ]. For a specific percentile and hour of life, the levels of bilirubin in the nomogram extrapolated from TcB measurements were generally lower than those of the TB nomogram.",
"   </p>",
"   <p>",
"    As a result, these nomograms are limited in their ability to accurately predict severe neonatal hyperbilirubinemia. At levels exceeding the 75th percentile, a confirmatory TB should be obtained. TcB measurements also are limited in infants undergoing phototherapy or who are darkly skinned, as the magnitude of hyperbilirubinemia cannot be accurately ascertained.",
"   </p>",
"   <p>",
"    There are significant variations among different instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/47\">",
"     47",
"    </a>",
"    ]. When TcB is used clinically as a substitute for TB, values of new instruments should always be compared to TB performed by the laboratory to ensure good correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     When to confirm with TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;A confirmatory TB should be measured in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/22,48\">",
"     22,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When TcB exceeds the 75th percentile on the TB nomogram for phototherapy (",
"      <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When the TcB exceeds the 95th percentile on the TcB nomogram.",
"     </li>",
"     <li>",
"      At follow-up after discharge, the TcB &gt;13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (222",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"     <li>",
"      When therapeutic intervention is being considered. Therapy should be initiated while awaiting confirmatory results.",
"     </li>",
"     <li>",
"      If the management plan would be altered by considering the TB to be equal to TcB + 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (51",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6163352\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of TcB screening reduces the number of blood tests for bilirubin determinations compared to visual assessment without compromising detection of infants with significant TB values (eg, &gt;75th percentile) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In addition, the implementation of TcB in a hospital- and community-screening program was associated with a reduction in the incidence of severe TB and readmission for phototherapy, and lower duration and rate of phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102138922\">",
"    <span class=\"h2\">",
"     Outpatient setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although, TcB measurements have been used as a screening tool to identify infants with hyperbilirubinemia, there are limited data regarding its reliability and accuracy in identifying at-risk infants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 120 infants (mean age 90.4 hours), there was good correlation between TcB and TB (r = 0.78) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/52\">",
"       52",
"      </a>",
"      ]. Although TcB values were lower than TB, TcB less than 12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (205",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      always reliably predicted that the TB was less than 15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (257",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      TcB values between 13 and 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (222 to 239",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      similarly predicted a TB &lt;17",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (291",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      The authors concluded that the use of TcB in the outpatient setting was a safe and reliable screen for assessing hyperbilirubinemia in infants recently discharged.",
"     </li>",
"     <li>",
"      In another study of 87 paired measurements of TcB and TB of term infants &le;8 days of age, mean TcB levels were greater than mean TSB (15.1 versus 13.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [258 versus 233",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/53\">",
"       53",
"      </a>",
"      ]. In comparison to inpatient measurements, there was greater variability between TcB and TB with outpatient measurements. In this study, the sensitivity of TcB to detect outpatient infants at risk for hyperbilirubinemia was 87 percent and the specificity was 58 percent. In contrast to the above study, the authors concluded that further studies are needed to determine the efficacy of outpatient TcB screening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other concerns regarding the use of TcB measurements in the outpatient setting is the initial cost of equipment, personnel time for training and performing the test, and the standardization of testing, such as body location for testing. For example, TcB measurements performed on the forehead in an infant who may have been exposed to direct sunlight may not be as reliable. A measurement made on an alternate site, such as the sternum, not exposed to sunlight, should be considered.",
"   </p>",
"   <p>",
"    As a result, before TcB outpatient measurements can be recommended for routine care, further studies are required to determine its efficacy and to optimize standardized protocols for its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     END-TIDAL CARBON MONOXIDE CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the breakdown of heme results in equimolar quantities of bilirubin and carbon monoxide (CO), end-tidal CO concentration corrected for ambient CO (ETCOc) provides a noninvasive assessment of bilirubin production [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. Elevated ETCOc values (&gt;2.0 ppm) can identify infants with increased bilirubin production due to increased red blood cell breakdown (eg, hemolysis), who may require additional evaluation, therapy, or close monitoring.",
"   </p>",
"   <p>",
"    In one study, the ETCOc value at 30 hours of age exceeded the mean value (1.48 ppm) in 76 percent of hyperbilirubinemic infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/54\">",
"     54",
"    </a>",
"    ]. In another study, ETCOc levels increased in infants with total serum or plasma bilirubin (TB) levels &gt;75th percentile, but decreased in nonjaundiced infants during the first four days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/59\">",
"     59",
"    </a>",
"    ]. These results suggest that increased heme catabolism is an important contributor to the development of hyperbilirubinemia.",
"   </p>",
"   <p>",
"    The combined use of an hour-specific TB measurement and ETCOc does NOT improve the predictive ability of an hour-specific TB testing alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/54\">",
"     54",
"    </a>",
"    ]. However, this dual approach can identify infants with increased bilirubin production (eg, hemolysis) or decreased elimination (eg, conjugation defects), who may need more intensive follow-up.",
"   </p>",
"   <p>",
"    Currently, commercial ETCOc instruments are not universally available, although a number of prototype devices are being developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BILIRUBIN/ALBUMIN RATIO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Term infants are at risk for bilirubin-induced neurologic dysfunction (BIND) when total serum or plasma bilirubin (TB) concentrations exceed 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (342",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    However, the relationship between TB and bilirubin toxicity is variable and influenced by other factors, such as binding of bilirubin to albumin. Unbound (or \"free\") bilirubin is more likely to cross the blood-brain barrier and cause brain injury. Most bilirubin is normally bound to albumin, resulting in low levels of unbound bilirubin. In patients with high TB concentrations, the capacity of albumin to bind bilirubin is exceeded, leading to higher levels of unbound bilirubin resulting in BIND.",
"   </p>",
"   <p>",
"    Although measurement of unbound bilirubin concentration would be useful to guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/60\">",
"     60",
"    </a>",
"    ], clinical testing is not universally available. The ratio of bilirubin to albumin",
"    <span class=\"nowrap\">",
"     (B/A)",
"    </span>",
"    can serve as an approximate surrogate for unbound bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     B/A",
"    </span>",
"    ratio is used only in conjunction with measurements of TB to determine whether therapeutic interventions (eg, exchange transfusion) should be initiated (",
"    <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Bilirubin/albumin ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preterm and sick infants often have decreased serum albumin concentrations and a reduced binding capacity, resulting in a higher proportion of unbound bilirubin for a given TB compared to healthy term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/62\">",
"     62",
"    </a>",
"    ]. As a result, in these patients, a lower",
"    <span class=\"nowrap\">",
"     B/A",
"    </span>",
"    ratio and TB thresholds are used to initiate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs such as sulfisoxazole, moxalactam, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    can displace bilirubin from albumin and increase the risk of bilirubin toxicity. Acidosis increases movement of bilirubin into tissues including the brain, and thus, can contribute to the development of BIND.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who have total serum or plasma bilirubin (TB) values &ge;95th percentile or suspicion of hemolytic disease require subsequent measurement(s) of TB and further evaluation to determine the etiology of jaundice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial tests that should be obtained are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood type and direct Coombs test",
"     </li>",
"     <li>",
"      Complete blood count and smear",
"     </li>",
"     <li>",
"      Reticulocyte count",
"     </li>",
"     <li>",
"      Glucose-6-phosphate dehydrogenase (G6PD) measurement, if clinically appropriate",
"     </li>",
"     <li>",
"      Direct or conjugated bilirubin",
"     </li>",
"     <li>",
"      ETCOc (if available)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TB should be repeated in 4 to 24 hours depending upon the infant's age, TB value, and anticipated rate of TB rise.",
"    <span class=\"nowrap\">",
"     Serum/plasma",
"    </span>",
"    albumin may be measured to help determine the need for interventions such as phototherapy or exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Bilirubin/albumin ratio'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Bilirubin/albumin ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mother's blood type usually should be known from prenatal testing. If either parent is of Mediterranean, Nigerian, or East-Asian ancestry, or if the TB concentration is &ge;18",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (308",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    G6PD should be measured. Because the turnaround time for G6PD results is currently not soon enough to affect clinical decisions, physicians taking care of infants with multi-cultural heritage should obtain a careful history of the",
"    <span class=\"nowrap\">",
"     ethnic/geographic",
"    </span>",
"    background of the family to better appreciate the risk of G6PD deficiency. If there is any clinical concern, it is prudent to provide parental education regarding avoidance of agents that trigger hemolysis until laboratory results are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For infants with other risk factors for severe hyperbilirubinemia, such as earlier gestational age (35 to 37 weeks gestation), further diagnostic workup and treatment may be initiated for lower TB concentrations (",
"    <a class=\"graphic graphic_table graphicRef64584 \" href=\"UTD.htm?23/29/24028\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Phototherapy indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the direct-reacting bilirubin is &gt;1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    when the TB is &lt;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (86",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    or &gt;20 percent of TB if the TB is &gt;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (86",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    causes of cholestatic jaundice should be considered. If there is a measurement of direct reacting that is &gt;1",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    the clinician should be advised to obtain repeat measurements over the next two or three days. If repeated measurements are abnormal, there is a need to investigate potential causes of cholestatic jaundice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=see_link\">",
"     \"Approach to neonatal cholestasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"       \"Patient information: Jaundice in babies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=see_link\">",
"       \"Patient information: Jaundice in newborn infants (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total",
"      <span class=\"nowrap\">",
"       serum/plasma",
"      </span>",
"      bilirubin (TB) &gt;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      occurs in almost all newborn infants and usually presents as jaundice. Infants with severe hyperbilirubinemia (TB &gt;25 to 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [428 to 513",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      are at risk for bilirubin-induced neurologic dysfunction (BIND), presenting acutely as acute bilirubin encephalopathy (ABE) and, if not adequately treated, long-term neurologic sequelae or kernicterus.",
"     </li>",
"     <li>",
"      Although the incidence of kernicterus is low, cases of kernicterus continue to occur. Contributing potentially correctable factors include early hospital discharge of newborn infants (&le;48 hours-of-life) without adequate follow-up, and failure to recognize and evaluate the severity of jaundice. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to identify and treat infants at risk for severe hyperbilirubinemia, we use a systemic approach to screen all term and late preterm infants as outlined by the American Academy of Pediatrics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Systematic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening includes bilirubin measurement in all infants who present with jaundice within the first 24 hours-of-life or who have jaundice in excess for their age (eg, jaundice below the level of the umbilicus). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Jaundice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are insufficient data that bilirubin screening will prevent kernicterus, experts in the field, including the authors, believe that severe hyperbilirubinemia is an acceptable clinical surrogate for kernicterus. In our practice, we perform universal bilirubin screening and clinical risk assessment before discharge to identify infants at high risk for severe hyperbilirubinemia. Alternatively, selective screening can be performed in which the need for bilirubin testing is determined by the presence of clinical risk factors for hyperbilirubinemia (",
"      <a class=\"graphic graphic_table graphicRef64584 \" href=\"UTD.htm?23/29/24028\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Universal screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Selective screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TB and transcutaneous (TcB) measurements can both be used to monitor bilirubin levels. However, at higher bilirubin concentrations, TcB measurements underestimate TB. Thus, when TcB exceeds the 75th percentile, TcB needs to be confirmed by measuring TB. TB and TcB values are compared to an age-specific percentile-based nomogram (",
"      <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Total serum or plasma bilirubin (TB)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Transcutaneous bilirubin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with TB &gt;95th percentile for age are at increased risk for severe hyperbilirubinemia and BIND. In some cases, phototherapy is initiated. Regardless of whether therapy is started, subsequent TB or TcB measurements are needed to direct further clinical care. In addition, further evaluation is performed to determine the etiology of jaundice. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Total serum or plasma bilirubin (TB)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Transcutaneous bilirubin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prior to discharge, risk assessment for severe hyperbilirubinemia should be performed, which (along with the age of the patient at discharge) guides the timing of the initial follow-up appointment (",
"      <a class=\"graphic graphic_table graphicRef64584 \" href=\"UTD.htm?23/29/24028\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65147 \" href=\"UTD.htm?7/58/8107\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the time of discharge, appropriate follow-up is arranged, information and written guidelines about jaundice are provided to the parents, and instructions when to contact medical staff are given to the family. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the follow-up appointment, the infant's weight and percent change from birth weight, adequacy of intake, pattern of voiding and stooling, and the presence or absence of jaundice are assessed. Clinical judgment based upon the infant's appearance and the interval medical history is used to determine the need for bilirubin measurement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although breastfeeding may be associated with persistent hyperbilirubinemia, the benefits of breast feeding are well established so that breastfeeding should be promoted and supported for term and late preterm infants.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/1\">",
"      Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/2\">",
"      Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/3\">",
"      Maisels MJ, Newman TB. Kernicterus in otherwise healthy, breast-fed term newborns. Pediatrics 1995; 96:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/4\">",
"      AAP Subcommittee on Neonatal Hyperbilirubinemia. Neonatal jaundice and kernicterus. Pediatrics 2001; 108:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/5\">",
"      Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr 2002; 140:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/6\">",
"      Johnson L, Bhutani VK, Karp K, et al. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009; 29 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/7\">",
"      Watchko JF. Vigintiphobia revisited. Pediatrics 2005; 115:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/8\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/9\">",
"      Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics 2006; 117:e855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/10\">",
"      Riskin A, Tamir A, Kugelman A, et al. Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia? J Pediatr 2008; 152:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/11\">",
"      Keren R, Tremont K, Luan X, Cnaan A. Visual assessment of jaundice in term and late preterm infants. Arch Dis Child Fetal Neonatal Ed 2009; 94:F317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/12\">",
"      Maisels MJ, Kring E. Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of &gt; or = 35 weeks' gestation. Pediatrics 2006; 117:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/13\">",
"      Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med 2005; 159:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/14\">",
"      Gon&ccedil;alves A, Costa S, Lopes A, et al. Prospective validation of a novel strategy for assessing risk of significant hyperbilirubinemia. Pediatrics 2011; 127:e126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/15\">",
"      Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics 2009; 124:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/16\">",
"      Mah MP, Clark SL, Akhigbe E, et al. Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening. Pediatrics 2010; 125:e1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/17\">",
"      Suresh GK, Clark RE. Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infants. Pediatrics 2004; 114:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/18\">",
"      Maisels MJ, Kring E. Transcutaneous bilirubinometry decreases the need for serum bilirubin measurements and saves money. Pediatrics 1997; 99:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/19\">",
"      Bhutani VK, Gourley GR, Adler S, et al. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics 2000; 106:E17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/20\">",
"      US Preventive Services Task Force. Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: US Preventive Services Task Force recommendation statement. Pediatrics 2009; 124:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/21\">",
"      Trikalinos TA, Chung M, Lau J, Ip S. Systematic review of screening for bilirubin encephalopathy in neonates. Pediatrics 2009; 124:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/22\">",
"      Maisels MJ, Bhutani VK, Bogen D, et al. Hyperbilirubinemia in the newborn infant &gt; or =35 weeks' gestation: an update with clarifications. Pediatrics 2009; 124:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/23\">",
"      Newman TB, Xiong B, Gonzales VM, Escobar GJ. Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med 2000; 154:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/24\">",
"      Keren R, Luan X, Friedman S, et al. A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants. Pediatrics 2008; 121:e170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/25\">",
"      Keren R, Bhutani VK, Luan X, et al. Identifying newborns at risk of significant hyperbilirubinaemia: a comparison of two recommended approaches. Arch Dis Child 2005; 90:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/26\">",
"      Profit J, Cambric-Hargrove AJ, Tittle KO, et al. Delayed pediatric office follow-up of newborns after birth hospitalization. Pediatrics 2009; 124:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/27\">",
"      Maisels MJ. What's in a name? Physiologic and pathologic jaundice: the conundrum of defining normal bilirubin levels in the newborn. Pediatrics 2006; 118:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/28\">",
"      Newman TB, Liljestrand P, Escobar GJ. Infants with bilirubin levels of 30 mg/dL or more in a large managed care organization. Pediatrics 2003; 111:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/29\">",
"      Ebbesen F, Andersson C, Verder H, et al. Extreme hyperbilirubinaemia in term and near-term infants in Denmark. Acta Paediatr 2005; 94:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/30\">",
"      Vreman HJ, Verter J, Oh W, et al. Interlaboratory variability of bilirubin measurements. Clin Chem 1996; 42:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/31\">",
"      Lo SF, Doumas BT, Ashwood ER. Performance of bilirubin determinations in US laboratories--revisited. Clin Chem 2004; 50:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/32\">",
"      Grohmann K, Roser M, Rolinski B, et al. Bilirubin measurement for neonates: comparison of 9 frequently used methods. Pediatrics 2006; 117:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/33\">",
"      Barko HA, Jackson GL, Engle WD. Evaluation of a point-of-care direct spectrophotometric method for measurement of total serum bilirubin in term and near-term neonates. J Perinatol 2006; 26:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/34\">",
"      Wainer S, Rabi Y, Parmar SM, et al. Impact of skin tone on the performance of a transcutaneous jaundice meter. Acta Paediatr 2009; 98:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/35\">",
"      Slusher TM, Angyo IA, Bode-Thomas F, et al. Transcutaneous bilirubin measurements and serum total bilirubin levels in indigenous African infants. Pediatrics 2004; 113:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/36\">",
"      Engle WD, Jackson GL, Sendelbach D, et al. Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population. Pediatrics 2002; 110:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/37\">",
"      Schumacher RE. Transcutaneous bilirubinometry and diagnostic tests: \"the right job for the tool\". Pediatrics 2002; 110:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/38\">",
"      Engle WD, Jackson GL, Stehel EK, et al. Evaluation of a transcutaneous jaundice meter following hospital discharge in term and near-term neonates. J Perinatol 2005; 25:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/39\">",
"      De Luca D, Romagnoli C, Tiberi E, et al. Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwavelength transcutaneous bilirubinometry. Acta Paediatr 2008; 97:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/40\">",
"      Varvarigou A, Fouzas S, Skylogianni E, et al. Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia. Pediatrics 2009; 124:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/41\">",
"      Engle WD, Lai S, Ahmad N, et al. An hour-specific nomogram for transcutaneous bilirubin values in term and late preterm Hispanic neonates. Am J Perinatol 2009; 26:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/42\">",
"      Sanpavat S, Nuchprayoon I, Smathakanee C, Hansuebsai R. Nomogram for prediction of the risk of neonatal hyperbilirubinemia, using transcutaneous bilirubin. J Med Assoc Thai 2005; 88:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/43\">",
"      Bental YA, Shiff Y, Dorsht N, et al. Bhutani-based nomograms for the prediction of significant hyperbilirubinaemia using transcutaneous measurements of bilirubin. Acta Paediatr 2009; 98:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/44\">",
"      Fouzas S, Mantagou L, Skylogianni E, et al. Transcutaneous bilirubin levels for the first 120 postnatal hours in healthy neonates. Pediatrics 2010; 125:e52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/45\">",
"      Yu ZB, Dong XY, Han SP, et al. Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants. Eur J Pediatr 2011; 170:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/46\">",
"      De Luca D, Jackson GL, Tridente A, et al. Transcutaneous bilirubin nomograms: a systematic review of population differences and analysis of bilirubin kinetics. Arch Pediatr Adolesc Med 2009; 163:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/47\">",
"      Ebbesen F, Vandborg PK, Trydal T. Comparison of the transcutaneous bilirubinometers BiliCheck and Minolta JM-103 in preterm neonates. Acta Paediatr 2012; 101:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/48\">",
"      Maisels MJ. Use TcB as a screening tool for jaundiced newborns. AAP News 2004; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/49\">",
"      Kaplan M, Shchors I, Algur N, et al. Visual screening versus transcutaneous bilirubinometry for predischarge jaundice assessment. Acta Paediatr 2008; 97:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/50\">",
"      Mishra S, Chawla D, Agarwal R, et al. Transcutaneous bilirubinometry reduces the need for blood sampling in neonates with visible jaundice. Acta Paediatr 2009; 98:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/51\">",
"      Wainer S, Parmar SM, Allegro D, et al. Impact of a transcutaneous bilirubinometry program on resource utilization and severe hyperbilirubinemia. Pediatrics 2012; 129:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/52\">",
"      Maisels MJ, Engle WD, Wainer S, et al. Transcutaneous bilirubin levels in an outpatient and office population. J Perinatol 2011; 31:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/53\">",
"      Wickremasinghe AC, Karon BS, Cook WJ. Accuracy of neonatal transcutaneous bilirubin measurement in the outpatient setting. Clin Pediatr (Phila) 2011; 50:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/54\">",
"      Stevenson DK, Fanaroff AA, Maisels MJ, et al. Prediction of hyperbilirubinemia in near-term and term infants. Pediatrics 2001; 108:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/55\">",
"      Stevenson DK, Vreman HJ. Carbon monoxide and bilirubin production in neonates. Pediatrics 1997; 100:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/56\">",
"      Bartoletti AL, Stevenson DK, Ostrander CR, Johnson JD. Pulmonary excretion of carbon monoxide in the human infant as an index of bilirubin production. I. Effects of gestational and postnatal age and some common neonatal abnormalities. J Pediatr 1979; 94:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/57\">",
"      Vreman HJ, Stevenson DK, Oh W, et al. Semiportable electrochemical instrument for determining carbon monoxide in breath. Clin Chem 1994; 40:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/58\">",
"      Stevenson DK, Vreman HJ, Oh W, et al. Bilirubin production in healthy term infants as measured by carbon monoxide in breath. Clin Chem 1994; 40:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/59\">",
"      Maisels MJ, Kring E. The contribution of hemolysis to early jaundice in normal newborns. Pediatrics 2006; 118:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/60\">",
"      Wennberg RP, Ahlfors CE. A different view on bilirubin binding. Pediatrics 2006; 118:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/61\">",
"      Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994; 93:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/39/11898/abstract/62\">",
"      Cashore WJ. Free bilirubin concentrations and bilirubin-binding affinity in term and preterm infants. J Pediatr 1980; 96:521.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5008 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11898=[""].join("\n");
var outline_f11_39_11898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYSTEMATIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Which infants require evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Breastfed infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Universal screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - USPSTF statement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Selective screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comparison of approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TOTAL SERUM OR PLASMA BILIRUBIN (TB)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Methods to measure bilirubin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chemical laboratory analyzers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Nonchemical photometric devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TRANSCUTANEOUS BILIRUBIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      When to confirm with TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6163352\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102138922\">",
"      Outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      END-TIDAL CARBON MONOXIDE CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BILIRUBIN/ALBUMIN RATIO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5008\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5008|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/51/19263\" title=\"figure 1\">",
"      Nomogram of hour-specific total bilirubin in term infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28464\" title=\"figure 2\">",
"      TSB guideline phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/44/21184\" title=\"figure 3\">",
"      TSB guide exchange transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5008|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/29/24028\" title=\"table 1\">",
"      Risk factors severe jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/58/8107\" title=\"table 2\">",
"      Follow-up neonatal jaundice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=related_link\" title=\"calculator 1\">",
"      Calculator: Newborn hyperbilirubinemia assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=related_link\">",
"      Initiation of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=related_link\">",
"      Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=related_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=related_link\">",
"      Patient information: Jaundice in newborn infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_39_11899="Tumor cell escape";
var content_f11_39_11899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some mechanisms of tumor cell escape from immunologic recognition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        T cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of tumor-specific molecules or peptide presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Downregulation of HLA-class I molecules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of costimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional defects in T cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        NK cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appropriate expression of self HLA class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soluble inhibitors of NK cell function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Both",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fas ligand expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heterogeneity and mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resistance to apoptosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11899=[""].join("\n");
var outline_f11_39_11899=null;
var title_f11_39_11900="Bronchiectasis by distribution";
var content_f11_39_11900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of bronchiectasis in children, based on distribution",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Localized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraluminal obstruction (granuloma, tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital abnormality (intralobar bronchopulmonary sequestration, bronchial stenosis, bronchomalacia, tracheal bronchus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extraluminal compression (lymphadenopathy ie, tuberculosis or vascular compression)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right middle lobe syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Upper lobe predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspiration syndrome in non-ambulating children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Central airways",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Allergic bronchopulmonary aspergillosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mounier-Kuhn symdrome (may also affect lower lobes if repeated infections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Lower lobes predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunodeficiency (specifically hypogammaglobulinemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic aspiration in ambulating children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitial pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Middle lobe and lingual predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary ciliary dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atypical mycobacterial infection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Javidan-Nejad C, Bhalla S, Bronchiectasis. Radiol Clin N Am 2009; 47:289.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11900=[""].join("\n");
var outline_f11_39_11900=null;
var title_f11_39_11901="Coronary artery stents approved in the United States";
var content_f11_39_11901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Coronary artery stents approved in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stent material",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Polymer (thickness) and Elution kinetics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Bare-metal stents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liberte",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Stainless steel",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bx Velocity",
"       </td>",
"       <td>",
"        Cordis/J&amp;J",
"       </td>",
"       <td>",
"        Stainless steel",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vision",
"       </td>",
"       <td>",
"        Abbott Vascular",
"       </td>",
"       <td>",
"        Cobalt chromium",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VeriFLEX",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Stainless steel",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Driver/Integrity",
"       </td>",
"       <td>",
"        Medtronic",
"       </td>",
"       <td>",
"        Cobalt chromium",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Drug-eluting stents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Taxus",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Stainless steel",
"       </td>",
"       <td>",
"        Paclitaxel",
"       </td>",
"       <td>",
"        SIBBS 16 micrometers; approximately 10% over 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Taxus Ion",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Platinum chromium",
"       </td>",
"       <td>",
"        Paclitaxel",
"       </td>",
"       <td>",
"        SIBBS 16 micrometers; approximately 10% over 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cypher",
"       </td>",
"       <td>",
"        Cordis/J&amp;J",
"       </td>",
"       <td>",
"        Stainless steel",
"       </td>",
"       <td>",
"        Sirolimus",
"       </td>",
"       <td>",
"        PEVA/PMBA 12.6 micrometers; &gt;80% within 4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Xience V/Prime",
"       </td>",
"       <td>",
"        Abbott Vascular",
"       </td>",
"       <td>",
"        Cobalt chromium",
"       </td>",
"       <td>",
"        Everolimus",
"       </td>",
"       <td>",
"        PMBA/PVDF-HFP 7.6 micrometers; 80% within 4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Promus",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Cobalt chromium",
"       </td>",
"       <td>",
"        Everolimus",
"       </td>",
"       <td>",
"        PMBA/PVDF-HFP 7.6 micrometers; 80% within 4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Promus element",
"       </td>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Platinum chromium",
"       </td>",
"       <td>",
"        Everolimus",
"       </td>",
"       <td>",
"        PMBA/PVDF-HFP 7.6 micrometers; 80% within 4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endeavor",
"       </td>",
"       <td>",
"        Medtronic",
"       </td>",
"       <td>",
"        Cobalt chromium",
"       </td>",
"       <td>",
"        Zotarolimus",
"       </td>",
"       <td>",
"        Phosphoryl Choline 5.3 micrometers; 95% within 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Resolute",
"       </td>",
"       <td>",
"        Medtronic",
"       </td>",
"       <td>",
"        Cobalt chromium",
"       </td>",
"       <td>",
"        Zotarolimus",
"       </td>",
"       <td>",
"        Biolynx* 5.6 micrometers; 85% within 8 weeks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SIBBS: styrene-b-isobutylene-b-styrene; PEVA: polyethylene-co-vinyl acetate; PBMA: poly n-butyl methacrylate; PBMA: poly(n-butyl methacrylate); PVDF-HFP: poly vinylidene fluoride &amp; hexafluoropropylene; %: percent.",
"     <br>",
"      * Proprietary polymer.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. J Dawn Abbott.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11901=[""].join("\n");
var outline_f11_39_11901=null;
var title_f11_39_11902="Effect of PGI2 and NO on PVR";
var content_f11_39_11902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effects of inhaled prostacyclin and inhaled nitric oxide on pulmonary hemodynamics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The approximately equivalent efficacy of inhaled prostacyclin (PGI2) and inhaled nitric oxide (NO) was demonstrated in eight patients with severe ARDS who were treated sequentially with both agents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Zwissler, B, Kemming, G, Habler, O, et al, Am J Respir Crit Care Med 1996; 154:1671.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11902=[""].join("\n");
var outline_f11_39_11902=null;
var title_f11_39_11903="Gelpi retractor";
var content_f11_39_11903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gelpi retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 209px; height: 375px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF3ANEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKK4nWPin4N0jUbixvNaj+026sZfKhkkRCEL7TIqlA+BwpbJOBjJFVbDxldeMdbvbDwNfaOtpp8MUlzqM6/bo3kkLbYo1ilUZAQlmMnGVG05yAD0CiuT+HPiw+KtO1QXEKxaho+pT6ReGMYjkmhIBkjBJIRgQQDyCSMtjcesoAKKKKACivO9Y8calZ6f4g1+O20+Pw1ok7wOZZWNxeeUds5TGFjKuGRFO7ey8mMEGsy8+Onhux1BrC+0/WY79VVzbwRw3bBTzkm3lkUcc4JBxg4wRkA9XorK8NeIdK8T6UmpaFeJd2bsV3hSpVh1VlYBlPTggHketatABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXHeNvBuiamlzqt1ealos8cRa6v9KvHtJJIkBOJSnDqBkjcCRzjGTnsa4H45ahJbfDm/wBOtPKOo666aJZpKSFeS5by+oBxhWdv+A0AeSfst6Jc6X4liuLbfFaX/hmG81CPzC2+5e7lELkEnkxIx7fe6c19M15f8EtItrW58XahY2r29lJqCaVaFyGMtvYwpbK4YdQXST9a9QoAK5j4n/2n/wAK68SnQpZIdTGnzNA8RKuGCE/KRyG64I6HFdPSEBgQwBB4IPegDwT4c/Drwv4s8NakLW+1m30n+1Z4pLCzvpIba6tlZPs6vH3DW4hbfw7byxY5BHuljZ2mmWMVrYW8FpZwLtjhhQRxxr6BRwBXiHwclh8O+PJdI+1RPFf2smmZZzva60uQwD5eil7VoJDjP3T6c+70AIrBlDKQVIyCOQRS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeG/FzxH5vi+7mtZC9r4H06TUJVIDxtqlyvl2UbIeWYbmYMAQCwGQeK9J+JXixPBvhK61NYmub9yLbT7RFLPdXT8RRKoOWyeSBzgMRnFeQ/DvwUbnxdpOlzs15F4fnOt+Ib0sWW81yUZSLdxkwqd2VJHIDAFjkA9e+F3hv8A4RH4e6BobIEmtLVROoYMPOb5pMEdRvZq6miigAooooA+bfitean4W8f+Jb+zW7mmtjY+K9PhhACOIl+x3iE7SdrRMC+OQFB6ZNfQegaxY+INFstW0i4W4sLyISwyr3U+o7EdCDyCCDyK5b4qeGrzV7Cy1jQIoZPEeiO9xZRzKpS5R0KTWz7uNsiErnjBCnIxmuD+FOtaV4S8V6f4Z0a4uJvB3ie1bVNBlnct9lnyfOsgefu43YJBVsqdzNmgD3SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuT+J3iG48PeGG/stS+uajKunaXHtyGupchCeCAqgM5LcYQ+1AHA+L/EMMviDWPGNxDJf6R4RZtM0nT0DZvNWchHcDvt3rEOGwfMZeRz6D8NPDDeFPCdvZ3ciz6tcO17qdyMf6RdyndK+QBkZ4HA+VVrgPDegW95490fwxYJ5vhjwFAkszyICLrVJFJVj2LIrNISOVeT6V7RQAUUUUAFFFFABXjnxB8LNqUuseF7S5Fpe3rf8JJ4dm3Mpt76Jh56qc8As6PkDObiU4+WvY65H4n6Zqd54djv/Dqq+vaPcLqNjGzELM6BleI4674nlTtywORjNADvhd4tTxp4NstUePyb9R5F9bkYMNwoG9cZPByGXn7rKa6yvBtC1m28IfGDS7iykDeFviJALq2kdFi8m4xvUdSzMxlIO4D/AFsag4jxXvNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeN674ntX8Q+LPGtx5Muk+B7abTrBZGAEuoOqmfnG5TzDAOo+Z8da9A+ImvP4c8IX99bLvvyot7OLeimS4kISNQXOPvMCc9geteRa9oZuNe+G3wwiYXAsCviDWnmJk80IxJ3MR83mSNLnI7qaAPS/g34cufDfgKyi1XLa3fM+o6nIygO9zMd77scFhkJn/ZrtqKKACiiigAooooAKKKKAPAvEfhZrnQ/F3gCwiMGo6PIPEXhgwMkUgjd2k2RbTlSk3nRAnGA6exr1D4UeL08deANI14CNLi4i23McfAjmU7XAGSQMgkAnO0is74lquh6noHjVXaNNKn+yahhtqvZXDKjs52kkRv5UvphG6ZyOV8EL/wAIJ8c/Efhd96aR4mT+2tL3H5FnGfPjUBcZPLdeFjTrkUAe0UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnPihV8S/Fnw9ocqs1hoMB1+5BjDRtOS0VsC3VWU+a4HfAPauT/Z5c+K/Fvj74gyqpj1O+FjYsY9jC3hUAHr3XygfdD+HMa14i+xfBr4jeOpGT7V4vvpLLTy2VZ7QE28QxzhljEz+/wCNeyfBXRF8PfCjwvp6o8bixjnlR/vLJL+8cH6M7CgDtaKKKACiiigAooooAKKKKAKOu6Zb61omoaXfKWtb63ktpQDglHUqefoa8B8YzajqXwl0PxSJxJ4u8A6g8V68bPKXeBvLmViMHbIFidjj7rc8EmvoyvKorSHTfjB4j8Paogk0Lxnp32yKF2CRmeNBDcxKo5LPGUdm4PHfHAB6To2pW2saRY6nYsXtL2CO5hYjBKOoZTjtwRVyvIP2abmew8Lav4O1J1OpeF9Rls2XnLQsxeOTnsxMmPZRXr9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXH/ABg1U6N8MvElzG8q3L2UltbeV98zyjy4woHJO9l6V2FcD8VYZNUvPB2hxtEI77Woppw/VordWnZV9yY159M0AeX/ABq0hY9P+EPwzVVmhmu4EuXRtr+XCixMeCOGWWUn/dr6Orwy/kHiD9rjTbdHLR+G9FeZ0yMLJICCTxk/LPHx7A+te50AFFFFABRRRQAUUUUAFFFFABXjn7SFxL4fsfCfjS0jkabw/q8bTNHjd9llUpMgzx82EX8e1ex1w/xx0iPXPhH4rs5VZtthJcoEGSXiHmoBj1ZAKAOZu8+G/wBpOwuVfZYeLtJeAqrcSXVthg7D2iwoPP3iK9erwDxlb6vqPwS8HeINKuIpdX0G5hvra6Y+V58CB1Tfk8GVPKyvOWbHQ17xY3cF/ZW93ZyLLbXEayxSL0dGGQR9QRQBPRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmmoFNQ/aI0i1nmGNJ8PTX1vDs/jmnETNux/dQDGc88d69Lrzrwoy33xs8eXEmGk0+z06wi+Y5VWWSZhj0JdefY+9AHB/A6FdV+PfxY1u5kkku7S5GnxsSceWZHUj8PsyAfSvoGvmz9j64F/qvxA1Btwmup7WWUNjJdvPZjgAAZLH5e3TmvpOgAooooAKKKKACiiigAooooAKbLGk0TxyorxuCrIwyGB6gjuKdRQB8/fB3TP7d+A2r6Je7hflC4iCsGiaNRHCxGcn57bIA7AcV6h8Hb+PUfhj4dkhR1SC2FmA/3j5BMJJ4GCTHkjHGcdq4L9nspaeM/ihpEKRpBZauWiEZyAjyzkKPTAGMeoNbn7PZa38NeIdKYMqaTr97ZIhbIQAq5A9syMfxoA9SooooAKKKKACiiigAooooAKKKKACiiigArg/A0O34j/EiUqoMl7ZDPcgWUP6cn9a7yuZ0aKG28feJY43zLcW1leSL6FvOiH6QUAeB/sSNJv8cxSuzlJbQlmPJP78Env2r6ir5h/ZfmTR/jB8S/De5Wbz5HVguARBcPGSPT/Wjivp6gAooooAKKKKACiiigAooooAKKKKAPKPhXAR8VvihcncPNuLRMMm0nYJhkHJyOcZ4+6eKvfCS3Nn4k+JFuu8Rf8JA04VsfekgidjkADnI98YyT1ND4Z6kj/EjxmLa2layu76WA3YwEW5tzh4mUchir5B4yEz1Nbvw12yeIPiFN8rOdfMZZQQMLaWwAwe4ycnvQB3dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYEsE0Pj23uI5H+z3WmyRSp/DvilQxnp1xNLW/WP4igHmaXfCF5XsbxZMIcEK6tCzH2VZS59l+lAHz3oFtJ4N/bJv7URAW3iK3llRunEieczY/66wsP1r6cr50/ajtn8N+LvAfxBtod39nXYtrshwGdFPmogB45AuBn3HtX0Jp95BqFhbXtnIJbW4iWaKQAgMjAFTz6gigCeiiigAooooAKKKKACiiigApk80dvBJNO6xxRqXd2OAqgZJNPrhPjnrX9hfCrxFNGrSXVzbGxt40bDvLP+6XaO5G/dgc4U0AYX7OenS2fgRbstHdJq97c6jJcLhdshZY9uMc52P8wJzjPO7jf+FSNInizUdqLBqHiC7kh2HIZYtlsW6nq0DHt16AYrU0a0sfAHw7t7eRithomnbpXAySsce53+pwx+pqv8JtPk034b+Hornzvtk1qt3ded9/z5szS59P3kj8dqAOtooooAKKKKACiiigAooooAKKKKACiiigAqnrNj/aekX1gZpIPtUDw+dEcPHuUjcvuM5FXKKAPPfFmlyfED4RXFtLEU1SS3LbMIXiu4iQ8YPKg71eMkZGC3UHnnf2WPGMHib4bx6aJHN3ob/Y2WVsuYOTCxxwBt+T6xmu20UR6D431TSQqx22sBtWtAMgGUbUuUA6DnypO24yyHsTXhOqzt8Fv2j3v2xF4U8UjfMd5WOIu4Dsc8ZSQ7vZJCB1oA+pKKKKACiiigAooooAKKKKACvJ/HlsnjH4weDtAhuWks9AMmuapAn3UkG0WoZsEbixc7DglCT3Fela5qltomi3+q37MlnYwPczFRkhEUscDucDpXE/BfQ7u30a98T66hXxD4nmGoXakk+RFj9xAM4IEcZAwRkEkc4FAC/HA3V94StfDenPNHd+JL+HSvNhI3Qwtl53IPVRFHICPevQgMAAZwPU5rzpAviX43NKEVrLwjYmIOysD9tuwCQpxtYLCgzzwZRXo1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzvjqzuJtGS/06N5dT0mYahaxJkmVkVg8QGQCZI2kjGcgFwcZArifjP4Wh+KHwrj1Hw+ZG1FbX+0NLlUFHlSSPLRHjOJIzjbx823PAr1iuM8KqvhzxTqXhj7tjdeZq+ljaAFV5P9JhGB/BK6yZJzi4CgYSgDj/2XvHzeMvh+ljqEpfWdF2205YktJER+6kJx1IBU8kkoSfvCvY6+WfiPaXfwb+MreOdJjkOiakUF3BtHlvG+BNErFs+YGRZVAxw3A2xtn6e0+8t9RsLa9sZlntLmJZoZU6OjAFWHsQQaALFFFFABRRRQAUUVl+KNdsvDOgXusao7LaWib22DLMSQFRR3ZmIUDuSKAOL+JQXxX4n0XwD5PnWNwBqutEjhbSJwYo+Rg+bMoHB3BUbjnNa3xA8dWng/wxq2r3HlOID9ms4txLXV2VJEQAHrgccjD5A285UWk22gafrdzqkj6drnjDUfszTxytO8TODHAqSbeAqKWAb5VZiAQMCuO0zRZvGXxUsNHv7g6joHgZBNeXONiahq0vzsxVW2jaSW287G3KeGoA9H+E/hafwn4OhttTkWfW72WTUNUnAA826lO5zxxxwuRgEKDgZrsaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlviHo13qWjw32jKDrukTDUNPGceZIoIaEnI+WRGeM+m/PYV1NFAHH3kWk/E/4dxT2M0b2mpW4ntZmAfyXIIw4Vu2WjkQMMguhOCa8n/Z28RXXhfxJqHw08QCSJo3kn0oSDlcEmWAnPOOXU4wy7mzhlz6bpKyeFPH11phQ/2J4ilkvrKT5j5N9t3Tw9wA6q0y9PmE3tXIftJ+BrvXdEtvFHhZB/wk2gSLcI8ZzI0UZLkIOhdThgO+CME7RQB7VRXn3wR+IcXxF8Fw38iJBq1tiG/t1P3ZMZDqOuxx8w9ORk7c16DQAUUUUAFcki2firxMk7kT2Og3DiFCoKNeAbDLnPPlhpYwOgfzMjKoRT+L/jGbwj4VkOlRrceIL/dbaZb7lDPMVOGAOd2OMKAdzFEHLirPwl8KS+Dfh3pGhX0q3F5DGz3Ug5DSyOzuM/xYLFcnqADx0oAw/id8QbPQNAvTFaR3XiSK/wD7O0myKiR5bx41KMi8kYSZSenXbn5hnf8Ahb4SPgzwZaaZcz/atUkLXWo3ZYu1zdSHdI5cgFueAzDJVVzXnXg+CL4k/GS+8SDyn8KeEGOm6PGir5Ut1tHmygZI+XjBAGR5RHKmvcqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMfxZocXiDRntHMcdzHIlzZ3Dx7/s9zGweKUDIztYAkZGRkHgmsLwbqWnX1tfeKnuf7NlZDb61YtcIYLW7g+SUu2OHULsL5AZFjPQKR2tcXqXlaH47ha5Ef8AZHidPskySY2fbY0PlkgnnzYVdDx/ywiHegDxT4iQ3HwK+K0PjTRYJZPC2vymPUbSMkqkhO5wAeAx5dOR0deFr6X06+tdS0+2vtPnjuLS4jWWGWM5V1IyCD9K86vNDtPGPhvWfh34ktbOOWxt41t57WMRRhNv7iaKHIZdmACFzHkMgc/Oi+S/s3+Nr7wR4ru/hb4zH2d0uWSxeRtqxynJMYLYykmQyEdS3Gd4wAfU9RXNxDaW0txdSxw28KGSSWRgqooGSxJ4AAGcmpa8v+JU8/jHxHZ/D3SncWkgW78RXMTEeRaA5W3JGMPMRj72QgJ2kGgDN8A6fc+PvHbfEPVY5F0WCJ7fQbeUkbkMhH2jZhdoKopAYEkuTnCRmrX7QnjC80bw5beG/DZkfxX4jf7HYpFwyISBJJnovB2g5GC24fdOOwuY7GLUEUXS2WieHbYSPa2+I4FbblQ+0cCONdwj6fvFYjhDXknwW834m/FXXfidfRsmmWOdL0WGQDcgx8zcHg7XOQcjMzYPy0AexfD3wvbeC/Bek+H7Nt8dlCEeTBHmSElpHwScbnLHGeM46CuhoooAKKKKACik5yeePSloAKKKKACiiigAooooAKKKKACiiigAooooAKO+KKKACsXxpo8mveF9Q0+1kWG9eMSWkzEgQ3KEPDIcf3ZFRsc524II4raooA8g1PWU13RPDHi5XFlfiCVZ1edkS0ljO2XIwWRFkDo8iq6bSGkjdFV4vPf2o/As+p6dp/xH8PW93aajAI0voBsWRAD+7m3Ixy6thcqWBGwqcLk+yaBY2Wp6p4r8PahCjx6ZqovbMp+7kh+0RCYyI64ZW82S4AYEHBI9a4T4marp/gfwhrHhPVBHrF1q8C2+j6Tbgl52YlQ5hRR5R3bchCEdlJjSMlloA2vA3xnsNa+EF14qvEjOp6YiwXtmj7S1ySFjA4+VZGK4JBAyRk7Sau+B7C+8OeB21KQRzeNvErtqMomRgJrkxtKttk8xosaFAGOF5x6HzX4Kfs9anpXlal4y1K4s2E8c40mzmVlYpuA85uVPDuuF5Cu2GG4geteO55INQQ6lJcw2UgGxbceaV8o+YtxCSuFnjOXaIhg8aMVD7GSgDjv2g76Lw58Hp7PwvbT2914qvxF5e1lmd7gtJLuV/mBYAoVI43hcDjHpvw28Lx+C/AujeH4mDmygCyOpJDysS0jDPOC7MQPQ15N8SLlfEn7TPw40CTZJp2nwPqyvESSZcO6liDjANvFj/ePXOK9+oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzbWTet4q8cW1rJNaSy6bpi29xGzk75JLlNygHg5AHHpzXm+q3jw/Fv4keL9QkFtJoC6fo+nzXJRhYrcskb3C9QNod5ACORIwPUiu61YGab4nSzGWcS3Ntp0UdvPsuAqWkUreSCCGkUTSOqfxMuDjOa4T4r3EngLxddeNbWyj1v4feMLKOy1uG3nA3lkZVkjK4wGjOQ2SCWcEqWRqAOs1WGXUvizZ+FvCF3qOnHTLdbzXdYilaWf7jC2t2eXerZ3lyrg5ABH3TXbeGp28cfDPT5r2SSK5vLVS9xGoQrOh/10fJGPMTeh542mvnbw1P4KvLSXSrT4rahpeja7Kbi/stQ00Q3U6sAjRyXhGwLhdvy/Ly/XPH1RNLp/hzR4F2R2mmWqx26hAFjgThF+ijgZ6AcnABNAHhV5Etv+2ZpzXaPvuNJLW7E8EiJwSB2GEcY9c19DV4R+0PGdB8d/DTxnG628VpqgsLyfAJ8qQg4+mwT/APfVe70AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXN/EYSS+C9Ts4I2eXUEXTl2nBU3DrDv+i+ZuPstAGB4d0l/EXw0upYjFDca3czarDMR94POZbZiwG4ERiEB1w67QVKsoI8s+LUVz4j174d/CmP5DOU1DWFTZGyoNxIJT5A20TMQAFLbCoAwK+j7G1gsLK3tLSMRW1vGsUSA5CoowB+AFeG/A9V8Z/Ffx38RY3jfT2m/sfT9ufnRBHmTB5GVSI/8AA26Y5APcZLG0l05rCW1gexeIwNbNGDGYyNpQr0244x0xXAeALGO1tfEXw91jFxa6eSLKOXcxk0ucHylLOxLbD5sPbAjXjkZ9HrhfiUF0GfTPGsMYDaQ/k6iygln0+UgSjABJ8thHNjr+6YD7xyAc34y8N3vjj4ea14SM1vdz2MMsccm8Gf7TEY2tsliQocCRSSWODgsGDCuu+EfioeMvh5o2svxdSReVdITysyEo+R2yQSAexFXo7NdK8Xm5Vn8jVU8oIANqTqC/YZwyhzycKVbHMhz5lp95qngH40a14a0fTBfaZ4mj/tixh8xYI7e54Sfc7clTt3sFDFRt2ocmgD2ea9tYLmG3nuYI7ibPlRPIA0mOu0Hk/hViuStvAOhzWsp8R2Flr2pXXzXd5fWyyNI3oobPlxr/AAoDhfckscOVj8MdWshJe3b+BLsJaf6W7TDR5+FjPmsS4gkztO8kIwXBVWwAD0miiigAqtqN/Z6ZZS3mpXUFpaRDdJPcSCNEHqWJAFch8TPiTpPgSCGCaOfUteu1P2HSbRS89y3QcAHapPG7B6HAYjFeBeI/Cnirxtcad4h+Mutr4e05nVLDRbaPzriZ2K7UhtgG+Y78EtvcYwyhRwAdP4u/aKa+1VdF+H2nmaed9kGoXVvLKJgW2kwQIu5yDuOTgfIeCSBXnviS5+MtnFaazq/iXUV1lp4Y7bRrGZTPubaVaa1iGwRnp8wJLbVK/Nke4+CvBs66Yo8NaPJ4N025jBlmuz5uqXamM7fNYMWi2sc7N+Rgfc5SvRtF8NaZpDxzQQLJeIrj7TIq+Zl23SEYAVd7fM20KGPJGaANeMsY0MihXIBYA5wadRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXL63G+p+NdAsfK3WunrLqk78/LJtMMKHt83mTN3wYR04rqK4bwrfmf8A4SfxRLAv+lXhsrHExYTW8BMUWDyAHmaZgQOkgPPWgBvxt8Q3Hh74e3x0z5tZ1J00vTkDYZriY7Bt4+8oLOP92sH4eWN58JfDNt4b1HRr7UdOhldxrOlQeeJN7u2ZbdczKwG1fkWRcbTuHIE3jIxeIvjf4M0Al5INFt59euoWXdGz8RW5PPDqxdhkccetdnrGu32kzAz6LPPZ+aN1zbyqypFtYlmBwQVKjIPy7SCGLfJQAaH4z8Oa7ZG60zWLSWEHDb38tlPONyvhh0PUdqfrOteGm0u4h1nVNJGn3ETxTLc3MYjdCMMDk4IwefrVK/8AF2jPJJY3ME8kbqvmC4tzHGY3yASZAFxnjaSCeoBHNR+Hr6y027vbWDQbbSdPEwVby18tYJCdoXcAFIY5AGAy5GN5PFAHE/DvxFbat8PbrRDHPqlx4duoLVAX+yT3FuHV7O4Tft+ZkEZUMQHZTzhhmb48pMPCejePtBjlGqeGrhb6ITRSRO1vJhJ42jbaQCu0ncAQFOCMnO98QYLbSfEGk69d28M2kXpGia1FKgaN4JmAgkkBYKQk2E5BwtxJVrw3pOpaZLc6Nraz6hpNzH5UTb/Ot9pVtyESFpk4BBDvIpyMMudgAGaFaXuo+IBr1tql7PpeoJFPbzRpAIntcM8cZyokAy5I4J+Y/MAdo5bUbz/hZfxUn8MvZ21z4W8LXC3N/KzRzR3Vw0RVLdo2B+6zSk9RlMEKQDXndv498UeC7+T4TafkX9hdGGy1Up9puGsmw0KJE2EebDgZYrGqrgjgtXV+AvhJrXhmxuLS++JGq2N/ql1JJFb20sZEmCWY4kDFpSuWYp09WAyQD3uvMvHHxCk8vUNP8JSxI9pcLZ6hrkyeZa6c5GSiIPmubnoqwxg4d1DEfdLfE2jQWtnDZeMPF3iPXvtpkig0a2MFs9+dhDRgW6RyMACS2XEYHL4AJqf4dfDttLuY9c8Typda0EZLS0iASz0mFwMwW8a4QcABnwC2PckgGB4Y8Ja1a6ndXPh7T5tP1LUFJ1Hxb4g8ue+mB3/LBbI21ACIsB9iqoUFHK4r0Pw14M0nQL6fUY1nvtauBtn1S+k865kXOdu7gInT5ECqMDjiukooAKKKKACiiigAooooAKKKjuoI7q2lt513RSoUdckZUjBGRzQBJRSKoVQo6AYFcvd+Iby/Rm8PxW0dgPvaxqDbbYdgY0BDTc45yiEHKuelAHU0V4drPxA8IRXHlat8Xb5peDJFo8MPkZx/A0cEjgd8GViPWt3wtqPhTxGqJ4a+JGqTXmNij+0UaYkH73kzIQc5AzsweMUAeqUjEgZClvYVx73Pivw5Gr3scXifT1LmSS0hFvexIASp8vcUnPTO0xn+6jE7a3/D2u6b4i01b/RrtLq2LFCQCrI46o6kBkYd1YAjuKAM7xvqd1oXg3Ury2kZ9SKCCz+QN/pMrCKFcAcjzHQcjoagstJhsodC8NWEzra6TDDNPjG6REBWJW7gtIu/I6+UQeGNVPEuNb8e+H9GRVkt9Kzrd9ujYhSA8dsuemTIZJB1I+z9sjOH8Y9RtvD3w08TavpoaXUvEEcdpb54d3lRYkVOMjapZwD33etAHC/DjwpP8Q/F/jD4gR63qujvcastrptxpziPzra3KqSwIKSo6qgwQV3IchulepW9n8QtLd1GqaBr9ukQEf2q3exnd9zcu8e9OF29EG48YTqdX4b+Gk8H+BND0FAm+ytlSYxklWlPzSMM84Llj+NdJQB57qPiXXWs7i21v4c390sccsji2uba6hl8s8FNzKx3cFQUDnn5eDSReJ/E7S3L6b8NLyK5LxwyPdX9rAGOMhiys5ZFQjkBiCSoBIOPQ6KAPLNesPH/AI38P6hpmo6bovh/T7uAwyW73JuriVWO0jzAmyIhcnISTJIxt6i54W8ex6d8NbvVPGdwBqGgTvpeqvEjEPcxuI1ZcqufM3RODgKPM5IAOPR68e8Q6bYWPxhuNI1uC2uPD3jyxKvFKWJF7bLtO3sgaFgMj5iyjBBAyAcN8WdcttRHhr4v+GLe4eHRrttL1OKRuTEJCFKsjmNwHZsMjMpLpyQpA7TRLTRNK0Wzh8L6b/afiDWI2jWMRJaQSAbTLPK0KhTbDcgyu9TlVTcW59CvfBWhz+Ap/B8Fmlroklo1okUQBMSkcON2cuD8245O7k5NfKPwE8QTfDD4z6l4b8YXKW8MqHTZJnbbFG8ZzE4LAHy2GQDgf6wE96APq/wj4UtfD8STyMt5q7W6W818YViyi9I441+WKIdo147ncxZj0decSfEwa9eXGn/DfTH8SXMJ2TX5k8jTrdunzTEEyEZU7Yw2Qeori/Fnh6bXNRi0v4heLNW17VpUWdfC/haEQQxrlQ4lJPMeSu2SZ4/4scnAAPSdU+KPgbTHkS68VaSZY+GihuBM+c4xtTJJz2xmqOmfGT4fajdtbReKbGCZQSy3oe0xjqCZVUA89Ov5VxVl8BvDdzPI7eDNI0u3wfKE2p3l5K3PG9BIiIcZ6O/OOazvF/7Nuh6j5b6XbR2cmMSPYzvEB0wRFL5gc4zx5keeOepIB9BwTRXEEc1vIksMihkdGDKwPQgjqKfXyLo/gT4gfDa+v7jwZr9tc3loYXfRmtRCbu3ZmLPKhO1sMQm9GfCswEibcV7x8IPifYfESxu4zay6Zr2nt5d/p0+d0RyRkEgZGQQRgFSMEdCQD0KiiigAooooAKKKyvEupRabppaW5W2aYmJJmIAi+Us0hLfKAiK7nPGENAHl/wAeviLZ+FvDzTSpHeLJK1vaWLHCXs6HEhlx1gjJG5Ry7/KcDJOJ8PfhNq/i8WXij4z6heapfHbLbaPNiOGBcE/vYwANxyDsAUDGG3ZKjjvgfozfFH4r3XjO9tPJ8M6AVt9KtWBwhTmGPqclAfMY5++wPQ19Y0AVNM02x0mzS00uztrK1T7sNtEsaL9FUAUuo6dZanbfZ9Ss7e8t9wbyriJZFyOhwQRkVaooA5zUrPVNHQ3XhwG8iUhpNJmk4dcnPkSMf3bcjCsTHhAoEeS4wdX8K2nivZ4l8Ha1d+H9auABJf2kf+v2Bk8u5gfAdkOVw4DoV28YIr0GuHvbCYeJda0RZXSx1mwN/abZSrW91GwSVkxyoy9u/H8ZdurGgCC3gPhSxu9M0u9vr/Wzc2uq6jeXgDvcxSXCxzPwNvyQxMoVANqrGB1Brk/GMR1v4xeAPA8Dz3Gn6DF/b19JI6liY8pbliMEkPjPqJAeea9E0qzWCeLVZbc2kUIuWzdS7WSK48ueQnJOCJF24O3ABxwAD51+zoT4k1bxx4/mUka3qRgsmljAkW1hGEGeccFVIHePvxQB7ZRRRQAUUUUAFcH8bvClx4u+Hl9a6WGGtWbJf6a6sVZLiI5XacjDEblBPA3Z7V3lFAHmGheOTrXh/wAJ+LLS9RLbVI1tLu0LjYJwSWWOJgHZwyyKNrZIwdkvGOa+Jfwb0P4g+N9M8XfbWXSjH5epxWyM8ly0bBUChQSp+8jnqoQDAOSItBhPhL4s+LvAj3LWml+K0OraXKiROsErhlmTY6lTuKkBSCNqKMfNXoMUl54O0vU7y/if+zdO0+a6K20oNofLUHCI+ZYThTiNS8ar0OcZAMTxFq8thqtn8N/hudP0/VHh86SSK2HlaPaZ+aVlzh5GLDYmOS25iAQT3PhDwzp3hPRl07S1lKl2mnuJ38ye6mbl5pXPLyMeST7AYAAHl37K9neXfg7VPGGszG51fxLfSXEs5PLRxkoq46ABvNwBjAIHQCva6ACiiigClqunRajCiy5SWMl4Z0wJIHwRvRiDg4JHQggkHIJFfOHxL8LX/hPWB4x8LwRWvibQ5POuQAqQX1qyhQVUkDBAddg+ZW3KuQYa+nK5P4iaVBd6UL+YRBbNXE7yEBRauAJicgj5AFmAxy0KjjOaANHwT4lsvGHhTTNf0st9lvovMCsOUYEqyH3VgyntxxxW3Xzx+y1qH9ja9418BXDSJJp14bq3il27gudkg+UkYBEfQ87s8V9D0AFFFFABXh37UPiZtH8H6rDbzFLh7NLMIwG1hduwJHfcI7aZfpITnjB9xr5i/bOnhTQraBpEFzNd2zqgHLIkdzyT2wZOP940Aenfs16DFoPwb0BURRNfRm/mcLgu0hypPuE2Ln/ZFen1zXwyhNv8N/CkDEEx6TaISOnEKCuloAKKKKACuY8SwKni7whfKjtObm4sSQ4AWKS2klbIxz81vGOMetdPXKeILqaXx/4T0yKOJogl5qUrkncvlosK47cm6PX0oA439pTW5/Dnwv1prGZo7zWXi023VIyzszkiQc5HzRKwGACOoOSMd94A8Ow+EvBejaFBsxY2yROyLtDyYy74ycbmLN1PWvM/FMR8cftFaDojL5uj+ErX+1bxcuFN0+PJUleNw/dOoPUCQcjIr2ugAooooAKKKKACiiigD5u/aO1KW+8XQQ2FzFp2u+ErRdd01biEZ1H5t0wjcsAFjSEMVIJchgBhcnpvjh4sg179mnUNe0SWRLfU4LbBR8MgeZBJGxHcfMjD6ivUPFfhTQvFtgLLxJpdrqFupygmT5ozxyjD5lPA5BGelfOGlaRPHB8TPgtOZREIn1Lw+rvyyhllSIMT82T5ZwB1EpNAHrf7M0nm/A7wuwOcJOv5XEg/pXp9fM/7Fni6O50PVvCdzIftNpIb62DHO6F8K4AxwFfB68+b7GvpigAooooAKZPFHPDJDMiyRSKUdGGQwPBBHpT6KAPlLwBeX1v+0t4curg4k13RytwmMFHigaFwxIycyWRbGeM/XP1bXyxo8rXH7TXw7un2BrzTLy92oThRO+oTKOefuyL+dfU9ABRRRQAV8x/tmaFLcafZ6ujLtgSMFB12B2V2P0aaED/ePTjP05XKfEnw0nijw5LZSoZImys8SRozywsCHVC33WHyup/vxpnIyCAUfgbqkGr/AAg8I3FqT5cenRWrZH8cI8pv/HkNdzXyr+zT4ol8A+M9Y+GfiuSG2Z7tms5n3Kr3HyrtUsBlZVCshOM8YyXAr6qoAKKKKACvLtN1S2XWPHHxF1CMNp2mW76XYsq4d4LUs87KS2G3zlkHA/1K+tdP411C9uF/4Rzw3dRw6/fRFjORu+wW5O1rlgCOeqxrn5n/ANlXK+V+J7S28ZeItG+E/hLH/CJ6AIpPEMqFtuyMjZalwRl2Kkt33c5yjCgDrP2edOvf+EMn8Ta4D/bXii6fVZ85wkbcRIuSTsCAMoJ4D47V6lTY40ijSOJFSNAFVVGAoHQAU6gAooooAKKKKACiiigArnvGnhiHxJYxeVcNYaxZsZtO1OJA0tnL/eAP3lOMMh4dcg+o6GgjIwelAHxD8R4dU+G/xMt/Hfh+1Sz/ANNaC+s0jbybe8EatNDuOQ0cyP5qN8p2yHCoU4+w/BfifTPGPhqy1zRJWks7pNwDgB426MjgE4YHIPJHoSMGqPjHwVp3ijzPtjSR+fCLW6CHieEMWUEZ4ZHO9HHKNnHDMD8q6ReeMfgL4p1J9MsH1TwpJOYp4y2ULIgb52AJgm2HOCMEHI8xQrUAfadFcl8P/iF4f8d2bS6HcyC4jRJJrO5Ty54VZQyll7ggghlJU5611tABWN4u1GfTdBuHsMHU58W1ipXduuH+WPI/ugncx7KrE8A1Z1/WdO8P6Rc6nrV5FZ2FuheSWU8AAZwB1J9AMkngA14Z8cPEmo6hbR6Ro6THxJrimz0TShEv2iKB+J7uZW/1JdN6Lu2siFydpMgjAMn4FpbeLfjv4k8S6Vvl8PaLYx6Xp8khPGFSNCgI4BWKVscY8wZHNfTNcP8ABnwJH8O/AdpopkjmvWY3F7NHnbJOwGduewAVQcDIUHAJNdxQAUUUUAFFFFAHjvx2+F+k+LdEjmkjaxubMBbbULaBppIAWJMciKNzQZbjbzGTkfJuFcp4N+JnjzwZpNtD498OXviPRFTMHiDRnS73xDIV3KEq+eMMxRscncTX0bXH618O9C1C4u7ux+3aFqN2Q095ol29lJM24tukCELI2Wbl1Y/MaAKek/FbwzqxlSyGuS3EIQ3EEeh3sjwb13KHCREDI5HPParOveI9VS1aaCCy0HTPJV31jXZlRIixGAIAwJOMj53jwSPvcismX4W3Um0D4i+OwoBBA1CIE+nIiFRwfBPwnNdwXfiFtX8TXkC7I5tb1CS5KjJOMZCkcngjHtQBxz+LbzxAbjwv8Gre4vZrkkar4wushEfIVn3lR5kmPu7cBQAI12qNvqHww8Cad8PvDS6Xp8ktzPI5nu7yb/WXMx6ufQcAAdgOSTknp7CztdPs4bSwtobW0hXZHDBGERF9FUcAfSp6ACiiigAooooAKKKKACiiigAooooAKw/Evhmy16GTzmltrpojB9pg27jGQQUdWDJIhDN8kisuTnGcEblFAHzX4r+Bjrrseo2mjS+aXJF14WvVsWjJHB+y3JZVA5UeXOoxj5RWNbReO9MsXh/4S74ntIuVET+FGuJOpP8ArTMynqQDv447AV9W0UAeA6F4Z8W3V9BJoHh6bSJ1TaPFHi+9GpaiiHKkxQbiIpME8fKrDg16R8O/hzpPgsSXiyT6n4iuogl/rN7I0lxcnOTyxOxc4+UdlXJYrmu2ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tips are designed to limit tissue penetration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_39_11903=[""].join("\n");
var outline_f11_39_11903=null;
